

A-527.ST25.txt
SEQUENCE LISTING

<110> FEIGE, ULRICH
LIU, CHUAN-FA
CHEETHAM, JANET C.
BOONE, THOMAS CHARLES

<120> MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

<130> A-527

<140> 09/428,082

<141> 1999-10-22

<150> 60/105,371

<151> 1998-10-23

<160> 1133

<170> PatentIn version 3.1

<210> 1

<211> 684

<212> DNA

<213> HUMAN

<220>

<221> CDS

<222> (1)..(684)

<223>

<400> 1

atg	gac	aaa	act	cac	aca	tgt	cca	cct	tgt	cca	gct	ccg	gaa	ctc	ctg	48
Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	
1				5					10					15		

ggg	gga	ccg	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	ctc	96
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	----

A-527.ST25.txt

Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	
			20					25					30			
atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	agc	144
Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	
		35					40					45				
cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	gag	192
His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	
	50					55					60					
gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	aac	agc	acg	240
Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	
65					70					75					80	
tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	aat	288
Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	
				85					90					95		
ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	ccc	336
Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	
			100					105					110			
atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	cag	384
Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	
		115					120					125				
gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	gtc	432
Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	
	130					135					140					
agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	480
Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	
145					150					155					160	
gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	cct	528
Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	
				165					170					175		
ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	576
Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	
			180					185					190			
gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	624
Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	
		195					200					205				
atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	672
Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	
	210					215					220					
tct	ccg	ggt	aaa													684
Ser	Pro	Gly	Lys													
225																

<210> 2

<211> 228

<212> PRT

<213> HUMAN

<400> 2

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys
225

<210> 3

<211> 36

<212> PRT

<213> Artificial sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (18)..(18)

<223> Methoxy-polyethylene glycol (5000 Dalton)-sulfoacetyl group attached to the sidechain.

<400> 3

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 4

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (18)..(18)

<223> Methoxy-polyethylene glycol (5000 Dalton)-succinimidyl group attached to the sidechain.

<400> 4

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210>	5
<211>	794
<212>	DNA
<213>	Artificial Sequence

<220>
<223> FC-TMP
<220>
<221> CDS
<222> (39) .. (779)
<223>

Genomic coordinates																Position
Genomic coordinates																Position
<div> <div><400></div> <div>5</div> <div>tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca</div> <div>Met Asp Lys Thr His Thr</div> <div>1 5</div> </div>																56
<div> <div>tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc</div> <div>Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe</div> <div>10 15 20</div> </div>																104
<div> <div>ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct</div> <div>Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro</div> <div>25 30 35</div> </div>																152
<div> <div>gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc</div> <div>Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val</div> <div>40 45 50</div> </div>																200
<div> <div>aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca</div> <div>Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr</div> <div>55 60 65 70</div> </div>																248
<div> <div>aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc</div> <div>Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val</div> <div>75 80 85</div> </div>																296
<div> <div>ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc</div> <div>Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys</div> <div>90 95 100</div> </div>																344
<div> <div>aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc</div> <div>Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser</div> <div>105 110 115</div> </div>																392
<div> <div>aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca</div> <div>Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro</div> <div>120 125 130</div> </div>																440
<div> <div>tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc</div> <div>Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val</div> <div>135 140 145 150</div> </div>																488
<div> <div>aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg</div> <div>Page 5</div> </div>																536

Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	
				155					160					165		
cag	ccg	gag	aac	aac	tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	584
Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	
			170					175					180			
ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	632
Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	
		185					190					195				
cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	680
Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	
	200					205					210					
aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	tct	ccg	ggt	aaa	ggt	gga	728
Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	Gly	Gly	
215					220				225						230	
ggt	ggt	ggt	atc	gaa	ggt	ccg	act	ctg	cgt	cag	tgg	ctg	gct	gct	cgt	776
Gly	Gly	Gly	Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	
				235					240					245		
gct	taatctcgag	gatcc														794
Ala																

<210> 6

<211> 247

<212> PRT

<213> Artificial Sequence

<220>

<223> FC-TMP

<400> 6

Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	
1				5					10					15		

Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	
			20					25					30			

Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	
		35					40					45				

His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	
	50					55					60					

Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	
65					70					75					80	

Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	
				85					90					95		

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
225 230 235 240

Gln Trp Leu Ala Ala Arg Ala
245

<210> 7
<211> 861
<212> DNA
<213> Artificial Sequence

<220>
<223> FC-TMP-TMP
<220>
<221> CDS
<222> (39)..(842)
<223>

<400> 7
tctagatttg ttttaactaa tttaaaggagg aataacat atg gac aaa act cac aca
Met Asp Lys Thr His Thr
1 5

A-527.ST25.txt

tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc	104		
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe			
10	15	20	
ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct	152		
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro			
25	30	35	
gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc	200		
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val			
40	45	50	
aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca	248		
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr			
55	60	65	70
aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc	296		
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val			
75	80	85	
ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc	344		
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys			
90	95	100	
aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc	392		
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser			
105	110	115	
aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca	440		
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro			
120	125	130	
tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc	488		
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val			
135	140	145	150
aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg	536		
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly			
155	160	165	
cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac	584		
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp			
170	175	180	
ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg	632		
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp			
185	190	195	
cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac	680		
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His			
200	205	210	
aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa ggt gga	728		
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly			
215	220	225	230
ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt	776		
Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg			
235	240	245	
gct ggt ggt gga ggt ggc ggc gga ggt att gag ggc cca acc ctt cgc	824		
Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg			
250	255	260	
caa tgg ctt gca gca cgc gcataatctc gaggatccg	861		
Gln Trp Leu Ala Ala Arg			
265			

<210> 8

<211> 268

<212> PRT

<213> Artificial Sequence

<220>

<223> Fc-TMP-TMP

<400> 8

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
 225 230 235 240

Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile
 245 250 255

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
 260 265

<210> 9

<211> 855

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-FC

<220>

<221> CDS

<222> (39)..(845)

<223>

<400> 9
 tctagatttg ttttaactaa ttaaaggagg aataacat atg atc gaa ggt ccg act 56
 Met Ile Glu Gly Pro Thr
 1 5

ctg cgt cag tgg ctg gct gct cgt gct ggc ggt ggt ggc gga ggg ggt 104
 Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly
 10 15 20

ggc att gag ggc cca acc ctt cgc caa tgg ctt gca gca cgc gca ggg 152
 Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly
 25 30 35

gga ggc ggt ggg gac aaa act cac aca tgt cca cct tgc cca gca cct 200
 Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
 40 45 50

gaa ctc ctg ggg gga ccg tca gtt ttc ctc ttc ccc cca aaa ccc aag 248
 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 55 60 65 70

gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg 296
 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 75 80 85

gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac 344
 Page 10

A-527.ST25.txt

Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	
			90					95					100			
ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	392
Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	
		105					110					115				
aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	440
Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	
	120					125					130					
tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	488
Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	
135					140					145					150	
cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	536
Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	
				155					160					165		
gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	584
Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	
			170					175					180			
aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	632
Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	
		185					190					195				
atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	680
Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	
	200					205					210					
acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	728
Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	
215					220				225						230	
aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	776
Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	
				235					240					245		
tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	824
Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	
			250					255					260			
ctc	tcc	ctg	tct	ccg	ggg	aaa	taatggatcc									855
Leu	Ser	Leu	Ser	Pro	Gly	Lys										
		265														

<210> 10

<211> 269

<212> PRT

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 10

Met	Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala	Gly
1				5					10					15	

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
 20 25 30
 Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys
 35 40 45
 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
 50 55 60
 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 65 70 75 80
 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 85 90 95
 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 100 105 110
 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 115 120 125
 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
 130 135 140
 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
 145 150 155 160
 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
 165 170 175
 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
 180 185 190
 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
 195 200 205
 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
 210 215 220
 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
 225 230 235 240
 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
 245 250 255
 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 260 265

<210> 11

<211> 789

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-Fc

<220>

<221> CDS

<222> (39)..(779)

<223>

<400> 11

tctagatttg	ttttaactaa	ttaaaggagg	aataacat	atg	atc	gaa	ggg	ccg	act		56					
				Met	Ile	Glu	Gly	Pro	Thr							
				1				5								
ctg	cgt	cag	tgg	ctg	gct	gct	cgt	gct	ggg	gga	ggc	ggg	gac	aaa	104	
Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala	Gly	Gly	Gly	Gly	Asp	Lys		
			10					15				20				
act	cac	aca	tgt	cca	cct	tgc	cca	gca	cct	gaa	ctc	ctg	ggg	gga	ccg	152
Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	
		25					30					35				
tca	gtt	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	ctc	atg	atc	tcc	200
Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	
	40					45					50					
cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	agc	cac	gaa	gac	248
Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	
55					60					65					70	
cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	gag	gtg	cat	aat	296
Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	
				75					80					85		
gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	aac	agc	acg	tac	cgt	gtg	344
Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	
			90					95					100			
gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	aat	ggc	aag	gag	392
Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	
		105					110					115				
tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	ccc	atc	gag	aaa	440
Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	
	120					125					130					
acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	cag	gtg	tac	acc	488
Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	
135					140					145					150	
ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	gtc	agc	ctg	acc	536
Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	
				155					160					165		
tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	gag	tgg	gag	584
Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	
			170					175					180			

A-527.ST25.txt

agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	cct	ccc	gtg	ctg	632
Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	
		185					190					195				
gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	gac	aag	680
Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	
	200					205					210					
agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	atg	cat	gag	728
Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	
	215				220					225					230	
gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	tct	ccg	ggt	776
Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	
				235					240					245		
aaa	taatggatcc															789
Lys																

<210> 12

<211> 247

<212> PRT

<213> Artificial Sequence

<220>

<223> TMP-Fc

<400> 12

Met	Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala	Gly
1				5				10						15	

Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro
			20					25					30		

Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys
		35					40					45			

Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val
	50					55					60				

Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp
65					70					75					80

Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr
				85					90					95	

Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp
			100					105					110		

Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu
		115					120					125			

A-527.ST25.txt

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
130 135 140

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
145 150 155 160

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
165 170 175

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
180 185 190

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
195 200 205

Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
210 215 220

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
225 230 235 240

Leu Ser Leu Ser Pro Gly Lys
245

<210> 13
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> TMP
<400> 13
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
1 5 10

<210> 14
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> TMP-TMP

<400> 14

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30

Ala Ala Arg Ala
 35

<210> 15

<211> 812

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP

<220>

<221> CDS

<222> (39)..(797)

<223>

<400> 15
 tctagatttg ttttaactaa tttaaaggagg aataacat atg gac aaa act cac aca 56
 Met Asp Lys Thr His Thr
 1 5

tgt cca cct tgt cca gct ccg gaa ctc ctg ggg gga ccg tca gtc ttc 104
 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
 10 15 20

ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152
 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
 25 30 35

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200
 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
 40 45 50

aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248
 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
 55 60 65 70

aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296
 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
 75 80 85

ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344
 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
 90 95 100

aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392

A-527.ST25.txt

Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser		
		105					110					115					
aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca		440
Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro		
	120					125					130						
tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc		488
Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val		
					140					145					150		
aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg		536
Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly		
				155					160					165			
cag	ccg	gag	aac	aac	tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac		584
Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp		
			170					175					180				
ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg		632
Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp		
		185					190					195					
cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac		680
Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His		
	200					205					210						
aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	tct	ccg	ggc	aaa	ggc	gga		728
Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	Gly	Gly		
					220					225					230		
ggc	ggc	ggc	gga	ggc	act	tac	tct	tgc	cac	ttc	ggc	ccg	ctg	act	tgg		776
Gly	Gly	Gly	Gly	Gly	Thr	Tyr	Ser	Cys	His	Phe	Gly	Pro	Leu	Thr	Trp		
				235				240						245			
gtt	tgc	aaa	ccg	cag	ggc	ggc	taatctcgtg	gatcc									812
Val	Cys	Lys	Pro	Gln	Gly	Gly											
			250														

<210> 16

<211> 253

<212> PRT

<213> Artificial sequence

<220>

<223> FC-EMP

<400> 16

Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu		
1				5					10					15			

Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu		
			20					25					30				

Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser		
		35				40						45					

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
225 230 235 240

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly
245 250

<210> 17

<211> 807

<212> DNA

<213> Artificial sequence

<220>

<223> EMP-FC

<220>

<221> CDS

<222> (39)..(797)

<223>

<400> 17

tctagatttg	ttttaactaa	ttaaaggagg	aataacat	atg	gga	ggt	act	tac	tct		56					
				Met	Gly	Gly	Thr	Tyr	Ser							
				1			5									
tgc	cac	ttc	ggc	ccg	ctg	act	tgg	gta	tgt	aag	cca	caa	ggg	ggt	ggg	104
Cys	His	Phe	Gly	Pro	Leu	Thr	Trp	Val	Cys	Lys	Pro	Gln	Gly	Gly	Gly	
			10					15					20			
gga	ggc	ggg	ggg	gac	aaa	act	cac	aca	tgt	cca	cct	tgc	cca	gca	cct	152
Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	
		25					30					35				
gaa	ctc	ctg	ggg	gga	ccg	tca	gtt	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	200
Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	
	40					45					50					
gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	248
Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	
55					60					65					70	
gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	296
Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	
				75					80					85		
ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	344
Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	
			90					95					100			
aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	392
Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	
		105					110					115				
tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	440
Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	
	120					125					130					
cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	488
Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	
135					140					145					150	
gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	536
Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	
				155					160					165		
aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	584
Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	
			170					175					180			
atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	632
Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	
		185					190					195				
acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	680
Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	
	200					205					210					
aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	728
Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	
215					220					225					230	

A-527.ST25.txt

tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 776
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
235 240 245

ctc tcc ctg tct ccg ggt aaa taatggatcc 807
Leu Ser Leu Ser Pro Gly Lys
250

<210> 18

<211> 253

<212> PRT

<213> Artificial sequence

<220>

<223> EMP-Fc

<400> 18

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10 15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys
20 25 30

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
35 40 45

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
50 55 60

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
65 70 75 80

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
85 90 95

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
100 105 110

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
115 120 125

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
130 135 140

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
145 150 155 160

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
165 170 175

A-527.ST25.txt

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
180 185 190

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
195 200 205

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
210 215 220

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
225 230 235 240

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
245 250

<210> 19
<211> 881
<212> DNA
<213> Artificial Sequence

<220>
<223> EMP-EMP-FC
<220>
<221> CDS
<222> (41)..(871)
<223>

<400> 19
tctagatttg agttttaact tttagaagga ggaataaaat atg gga ggt act tac 55
Met Gly Gly Thr Tyr
1 5

tct tgc cac ttc ggc cca ctg act tgg gtt tgc aaa ccg cag ggt ggc 103
Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly
10 15 20

ggc ggc ggc ggc ggt ggt acc tat tcc tgt cat ttt ggc ccg ctg acc 151
Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr
25 30 35

tgg gta tgt aag cca caa ggg ggt ggg gga ggc ggg ggg gac aaa act 199
Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Asp Lys Thr
40 45 50

cac aca tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg tca 247
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
55 60 65

gtt ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg 295

A-527.ST25.txt

Val 70	Phe	Leu	Phe	Pro	Pro 75	Lys	Pro	Lys	Asp	Thr 80	Leu	Met	Ile	Ser	Arg 85	
acc Thr	cct Pro	gag Glu	gtc Val	aca Thr 90	tgc Cys	gtg Val	gtg Val	gtg Val	gac Asp 95	gtg Val	agc Ser	cac His	gaa Glu	gac Asp 100	cct Pro	343
gag Glu	gtc Val	aag Lys	ttc Phe 105	aac Asn	tgg Trp	tac Tyr	gtg Val	gac Asp 110	ggc Gly	gtg Val	gag Glu	gtg Val	cat His 115	aat Asn	gcc Ala	391
aag Lys	aca Thr	aag Lys 120	ccg Pro	cgg Arg	gag Glu	gag Glu	cag Gln 125	tac Tyr	aac Asn	agc Ser	acg Thr	tac Tyr 130	cgt Arg	gtg Val	gtc Val	439
agc Ser	gtc Val 135	ctc Leu	acc Thr	gtc Val	ctg Leu	cac His 140	cag Gln	gac Asp	tgg Trp	ctg Leu	aat Asn 145	ggc Gly	aag Lys	gag Glu	tac Tyr	487
aag Lys 150	tgc Cys	aag Lys	gtc Val	tcc Ser	aac Asn 155	aaa Lys	gcc Ala	ctc Leu	cca Pro	gcc Ala 160	ccc Pro	atc Ile	gag Glu	aaa Lys	acc Thr 165	535
atc Ile	tcc Ser	aaa Lys	gcc Ala	aaa Lys 170	ggg Gly	cag Gln	ccc Pro	cga Arg	gaa Glu 175	cca Pro	cag Gln	gtg Val	tac Tyr	acc Thr 180	ctg Leu	583
ccc Pro	cca Pro	tcc Ser	cgg Arg 185	gat Asp	gag Glu	ctg Leu	acc Thr	aag Lys 190	aac Asn	cag Gln	gtc Val	agc Ser	ctg Leu 195	acc Thr	tgc Cys	631
ctg Leu	gtc Val	aaa Lys 200	ggc Gly	ttc Phe	tat Tyr	ccc Pro	agc Ser 205	gac Asp	atc Ile	gcc Ala	gtg Val	gag Glu 210	tgg Trp	gag Glu	agc Ser	679
aat Asn 215	ggg Gly	cag Gln	ccg Pro	gag Glu	aac Asn	aac Asn 220	tac Tyr	aag Lys	acc Thr	acg Thr	cct Pro 225	ccc Pro	gtg Val	ctg Leu	gac Asp	727
tcc Ser 230	gac Asp	ggc Gly	tcc Ser	ttc Phe	ttc Phe 235	ctc Leu	tac Tyr	agc Ser	aag Lys	ctc Leu 240	acc Thr	gtg Val	gac Asp	aag Lys	agc Ser 245	775
agg Arg	tgg Trp	cag Gln	cag Gln	ggg Gly 250	aac Asn	gtc Val	ttc Phe	tca Ser	tgc Cys 255	tcc Ser	gtg Val	atg Met	cat His	gag Glu 260	gct Ala	823
ctg Leu	cac His	aac Asn	cac His 265	tac Tyr	acg Thr	cag Gln	aag Lys	agc Ser 270	ctc Leu	tcc Ser	ctg Leu	tct Ser	ccg Pro 275	ggg Gly	aaa Lys	871
taatggatcc															881	
<210> 20																
<211> 277																
<212> PRT																
<213> Artificial Sequence																
<220>																
<223> EMP-EMP-Fc																

<400> 20

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
 1 5 10 15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
 20 25 30

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
 35 40 45

Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
 50 55 60

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
 65 70 75 80

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
 85 90 95

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
 100 105 110

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
 115 120 125

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
 130 135 140

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
 145 150 155 160

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
 165 170 175

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
 180 185 190

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
 195 200 205

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
 210 215 220

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
 225 230 235 240

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
 245 250 255

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
 260 265 270

Leu Ser Pro Gly Lys
275

<210> 21

<211> 885

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP-EMP

<220>

<221> CDS

<222> (39)..(869)

<223>

<400> 21
tctagatttg ttttaactaa ttaaaggagg aataacat atg gac aaa act cac aca 56
Met Asp Lys Thr His Thr
1 5

tgt cca cct tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc 104
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
10 15 20

ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct 152
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
25 30 35

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc 200
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
40 45 50

aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca 248
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
55 60 65 70

aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc 296
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
75 80 85

ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc 344
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
90 95 100

aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc 392
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
105 110 115

aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg cct cca 440
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
120 125 130

tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc 488

A-527.ST25.txt

Ser 135	Arg	Asp	Glu	Leu	Thr 140	Lys	Asn	Gln	Val	Ser 145	Leu	Thr	Cys	Leu	Val 150	
aaa Lys	ggc Gly	ttc Phe	tat Tyr	ccc Pro 155	agc Ser	gac Asp	atc Ile	gcc Ala	gtg Val 160	gag Glu	tgg Trp	gag Glu	agc Ser	aat Asn 165	ggg Gly	536
cag Gln	ccg Pro	gag Glu	aac Asn 170	aac Asn	tac Tyr	aag Lys	acc Thr	acg Thr 175	cct Pro	ccc Pro	gtg Val	ctg Leu	gac Asp 180	tcc Ser	gac Asp	584
ggc Gly	tcc Ser	ttc Phe 185	ttc Phe	ctc Leu	tac Tyr	agc Ser	aag Lys 190	ctc Leu	acc Thr	gtg Val	gac Asp	aag Lys 195	agc Ser	agg Arg	tgg Trp	632
cag Gln	cag Gln 200	ggg Gly	aac Asn	gtc Val	ttc Phe	tca Ser 205	tgc Cys	tcc Ser	gtg Val	atg Met	cat His 210	gag Glu	gct Ala	ctg Leu	cac His	680
aac Asn 215	cac His	tac Tyr	acg Thr	cag Gln	aag Lys 220	agc Ser	ctc Leu	tcc Ser	ctg Leu	tct Ser 225	ccg Pro	ggt Gly	aaa Lys	ggt Gly	gga Gly 230	728
ggt Gly	ggt Gly	ggc Gly	gga Gly	ggt Gly 235	act Thr	tac Tyr	tct Ser	tgc Cys	cac His 240	ttc Phe	ggc Gly	cca Pro	ctg Leu	act Thr 245	tgg Trp	776
gtt Val	tgc Cys	aaa Lys	ccg Pro 250	cag Gln	ggt Gly	ggc Gly	ggc Gly	ggc Gly 255	ggc Gly	ggc Gly	ggt Gly	ggt Gly	acc Thr 260	tat Tyr	tcc Ser	824
tgt Cys	cat His	ttt Phe 265	ggc Gly	ccg Pro	ctg Leu	acc Thr	tgg Trp 270	gta Val	tgt Cys	aag Lys	cca Pro	caa Gln 275	ggg Gly	ggt Gly		869
taatctcgag gatcca															885	

<210> 22
 <211> 277
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> FC-EMP-EMP
 <400> 22

Met 1	Asp	Lys	Thr	His 5	Thr	Cys	Pro	Pro	Cys 10	Pro	Ala	Pro	Glu	Leu 15	Leu
Gly	Gly	Pro	Ser 20	Val	Phe	Leu	Phe	Pro 25	Pro	Lys	Pro	Lys	Asp 30	Thr	Leu
Met	Ile	Ser 35	Arg	Thr	Pro	Glu	Val 40	Thr	Cys	Val	Val	Val 45	Asp	Val	Ser
His 50	Glu	Asp	Pro	Glu	Val	Lys 55	Phe	Asn	Trp	Tyr	Val 60	Asp	Gly	Val	Glu

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80
 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95
 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110
 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125
 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140
 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160
 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175
 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190
 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 195 200 205
 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220
 Ser Pro Gly Lys Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
 225 230 235 240
 Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
 245 250 255
 Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
 260 265 270
 Lys Pro Gln Gly Gly
 275

<210> 23
 <211> 1546
 <212> DNA
 <213> Artificial Sequence

<220>

<223> pAMG21

<400> 23

gCGtaacgta	tgc	atggtct	cccc	atgcga	gagtagggaa	ctgccaggca	tcaaataaaa	60
cgaaaggctc	agtc	gaaaga	ctgggccttt	cgttttatct	gttgtttgct	ggtgaacgct		120
ctcctgagta	ggaca	aatcc	gccgggagcg	gatttgaacg	ttgcgaagca	acggcccgga		180
gggtggcggg	caggac	gccc	gccataaact	gccaggcatc	aaattaagca	gaaggccatc		240
ctgacggatg	gcctttttgc	gtttct	tacaa	actcttttgc	ttatttttct	aaatacattc		300
aaatatggac	gtcgtactta	acttttta	aaag	tatgggcaat	caattgctcc	tgttaaaatt		360
gcttttagaaa	tactttggca	gcgggtttg	tt	gtattgagtt	tcatttgcgc	attggttaaa		420
tggaaagtga	ccgtgcgctt	actacagcct	aatat	ttttgc	aaatatccca	agagcttttt		480
ccttcgcatg	cccacgctaa	acattctttt	tctcttttgc	ttaaatcggt	gtttgattta			540
ttatttgcta	tattttatttt	tcgataatta	tcaactagag	aaggaacaat	taatggatatg			600
ttcatacacg	catgtaaaaa	taaactatct	atatagttgt	ctttctctga	atgtgcaaaa			660
ctaagcattc	cgaagccatt	attagcagta	tgaataggga	aactaaaccc	agtgataaga			720
cctgatgatt	tcgcttcttt	aattacattt	ggagattttt	tattttacagc	attgtttttca			780
aatatatattcc	aattaatcgg	tgaatgattg	gagttagaat	aatctactat	aggatcatat			840
tttatttaa	at	tagcgtcatc	ataatattgc	ctccattttt	tagggtaatt	atccagaatt		900
gaaatatcag	atttaaccat	agaatgagga	taaatgatcg	cgagtaaata	atattcacia			960
tgtaccattt	tagtcatatc	agataagcat	tgattaatat	cattattgct	tctacaggct			1020
ttaattttat	taattattct	gtaagtgtcg	tcggcattta	tgtctttcat	acccatctct			1080
ttatccttac	ctattgtttg	tcgcaagttt	tgcgtgttat	atatcattaa	aacggtaata			1140
gattgacatt	tgattcta	aat	tggtgatt	tttgtcacac	tattatatcg	cttgaaatac		1200
aattgtttta	cataagtacc	tgtaggatcg	tacaggttta	cgcaagaaaa	tggtttggtta			1260
tagtcgatta	atcgatttga	ttctagattt	gttttaacta	attaaaggag	gaataacata			1320
tggttaacgc	gttggaattc	gagctcacta	gtgtcgacct	gcagggtacc	atggaagctt			1380
actcgaggat	ccgcggaaag	aagaagaaga	agaagaaagc	ccgaaaggaa	gctgagttgg			1440
ctgctgccac	cgctgagcaa	taactagcat	aacccttgg	ggcctctaaa	cgggtcttga			1500
gggggtttttt	gctgaaagga	ggaaccgctc	ttcacgctct	tcacgc				1546

<210> 24

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 24

Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Lys	Ala
1				5					10				

<210> 25

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 25

Ile	Glu	Gly	Pro	Thr	Leu	Arg	Glu	Trp	Leu	Ala	Ala	Arg	Ala
1				5					10				

<210> 26

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<400> 26

Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala
1				5					10				

<210> 27

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<400> 27

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Lys Ala
1 5 10

<210> 28

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (9)..(9)

<223> At position 9 disulfide linkage to position 9 of an identical sequence

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<400> 28

Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala
1 5 10

<210> 29

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (16)..(16)

<223> Position 16 bromoacetyl group linked to sidechain

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker attached N-to-C to Lys and to a
nother linker and an identical sequence

<400> 29

Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala
1				5					10				

<210> 30

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (16)..(16)

<223> Position 16 polyethylene glycol linked to sidechain

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker attached N-to-C to Lys and to a
nother linker and an identical sequence

<400> 30

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
1 5 10

<210> 31

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (9)..(9)

<223> Position 9 disulfide bond to residue 9 of a separate identical sequence

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<400> 31

Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala
1 5 10

<210> 32

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker attachment site

<400> 32

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
1 5 10

<210> 33

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (6, 7 and)..(8)

<223> Xaa = any amino acid

<400> 33

Val Arg Asp Gln Ile Xaa Xaa Xaa Leu
1 5

<210> 34

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 34

Thr Leu Arg Glu Trp Leu
1 5

<210> 35

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 35

Gly Arg Val Arg Asp Gln Val Ala Gly Trp
1 5 10

<210> 36

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 36

Gly Arg Val Lys Asp Gln Ile Ala Gln Leu
1 5 10

<210> 37

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 37

Gly Val Arg Asp Gln Val Ser Trp Ala Leu
1 5 10

<210> 38

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 38

Glu Ser Val Arg Glu Gln Val Met Lys Tyr
1 5 10

<210> 39

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 39

Ser Val Arg Ser Gln Ile Ser Ala Ser Leu
1 5 10

<210> 40

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 40

Gly Val Arg Glu Thr Val Tyr Arg His Met
1 5 10

<210> 41

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 41

Gly Val Arg Glu Val Ile Val Met His Met Leu
1 5 10

<210> 42

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 42

Gly Arg Val Arg Asp Gln Ile Trp Ala Ala Leu
1 5 10

<210> 43

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 43

Ala Gly Val Arg Asp Gln Ile Leu Ile Trp Leu
1 5 10

<210> 44

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 44

Gly Arg Val Arg Asp Gln Ile Met Leu Ser Leu
1 5 10

<210> 45

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (8)..(10)

<223> Xaa = any amino acid

<400> 45

Gly Arg Val Arg Asp Gln Ile Xaa Xaa Xaa Leu
1 5 10

<210> 46

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 46

Cys Thr Leu Arg Gln Trp Leu Gln Gly Cys
1 5 10

<210> 47

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 47

Cys Thr Leu Gln Glu Phe Leu Glu Gly Cys
1 5 10

<210> 48

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 48

Cys Thr Arg Thr Glu Trp Leu His Gly Cys
1 5 10

<210> 49

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 49

Cys Thr Leu Arg Glu Trp Leu His Gly Gly Phe Cys
1 5 10

<210> 50

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 50

Cys Thr Leu Arg Glu Trp Val Phe Ala Gly Leu Cys
1 5 10

<210> 51

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 51

Cys Thr Leu Arg Gln Trp Leu Ile Leu Leu Gly Met Cys
 1 5 10

<210> 52

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 52

Cys Thr Leu Ala Glu Phe Leu Ala Ser Gly Val Glu Gln Cys
 1 5 10

<210> 53

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 53

Cys Ser Leu Gln Glu Phe Leu Ser His Gly Gly Tyr Val Cys
 1 5 10

<210> 54

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 54

Cys Thr Leu Arg Glu Phe Leu Asp Pro Thr Thr Ala Val Cys
 1 5 10

<210> 55

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 55

Cys Thr Leu Lys Glu Trp Leu Val Ser His Glu Val Trp Cys
1 5 10

<210> 56

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (8)..(9)

<223> Xaa = any amino acid

<400> 56

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Cys
1 5 10

<210> 57

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (8)..(10)

<223> Xaa = any amino acid

<400> 57

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Cys
1 5 10

<210> 58

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (8)..(11)

<223> Xaa = any amino acid

<400> 58

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Cys
1 5 10

<210> 59

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (8)..(12)

<223> Xaa = any amino acid

<400> 59

Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Xaa Cys
1 5 10

<210> 60
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE
 <220>
 <221> misc_feature
 <222> (8)..(13)
 <223> Xaa = any amino acid

<400> 60
 Cys Thr Leu Arg Glu Trp Leu Xaa Xaa Xaa Xaa Xaa Xaa Cys
 1 5 10

<210> 61
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 61
 Arg Glu Gly Pro Thr Leu Arg Gln Trp Met
 1 5 10

<210> 62
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TPO-MIMETIC PEPTIDE

<400> 62
 Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
 1 5 10

<210> 63

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 63

Glu Arg Gly Pro Phe Trp Ala Lys Ala Cys
1 5 10

<210> 64

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 64

Arg Glu Gly Pro Arg Cys Val Met Trp Met
1 5 10

<210> 65

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 65

Cys Gly Thr Glu Gly Pro Thr Leu Ser Thr Trp Leu Asp Cys
1 5 10

<210> 66

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 66

Cys Glu Gln Asp Gly Pro Thr Leu Leu Glu Trp Leu Lys Cys
1 5 10

<210> 67

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 67

Cys Glu Leu Val Gly Pro Ser Leu Met Ser Trp Leu Thr Cys
1 5 10

<210> 68

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 68

Cys Leu Thr Gly Pro Phe Val Thr Gln Trp Leu Tyr Glu Cys
1 5 10

<210> 69

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 69

Cys Arg Ala Gly Pro Thr Leu Leu Glu Trp Leu Thr Leu Cys
1 5 10

<210> 70

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 70

Cys Ala Asp Gly Pro Thr Leu Arg Glu Trp Ile Ser Phe Cys
1 5 10

<210> 71

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2)..(12)

<223> Xaa = any amino acid

<400> 71

Cys Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Cys
1 5 10

<210> 72

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 3)..(13)

<223> Xaa = any amino acid

<400> 72

Cys Xaa Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Cys
1 5 10

<210> 73

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 12)..(13)

<223> Xaa = any amino acid

<400> 73

Cys Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Xaa Cys
1 5 10

<210> 74

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 3, 13)..(14)

<223> xaa = any amino acid

<400> 74

Cys Xaa Xaa Glu Gly Pro Thr Leu Arg Glu Trp Leu Xaa Xaa Cys
1 5 10 15

<210> 75

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 75

Gly Gly Cys Thr Leu Arg Glu Trp Leu His Gly Gly Phe Cys Gly Gly
1 5 10 15

<210> 76

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 76

Gly Gly Cys Ala Asp Gly Pro Thr Leu Arg Glu Trp Ile Ser Phe Cys
1 5 10 15

Gly Gly

<210> 77

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 77

Gly Asn Ala Asp Gly Pro Thr Leu Arg Gln Trp Leu Glu Gly Arg Arg
1 5 10 15

Pro Lys Asn

<210> 78

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 78

Leu Ala Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu His Gly Asn Gly
1 5 10 15

Arg Asp Thr

<210> 79

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 79

His Gly Arg Val Gly Pro Thr Leu Arg Glu Trp Lys Thr Gln Val Ala
1 5 10 15

Thr Lys Lys

<210> 80

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 80

Thr Ile Lys Gly Pro Thr Leu Arg Gln Trp Leu Lys Ser Arg Glu His
1 5 10 15

Thr Ser

<210> 81

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDE

<400> 81

Ile Ser Asp Gly Pro Thr Leu Lys Glu Trp Leu Ser Val Thr Arg Gly
1 5 10 15

Ala Ser

<210> 82

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO MIMETIC PEPTIDE

<400> 82

Ser Ile Glu Gly Pro Thr Leu Arg Glu Trp Leu Thr Ser Arg Thr Pro
1 5 10 15

His Ser

<210> 83

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 4, 5, 8, 11)..(13)

<223> Xaa = any amino acid

<400> 83

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
1 5 10

<210> 84

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 4, 5, 8, 11, 13, 16, 18, 19, 22, 25)..(27)

<223> Xaa = any amino acid

<400> 84

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro Tyr Xaa
1 5 10 15

Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
20 25

<210> 85

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (14)..(14)

<223> At position 14, amino acid linker to an identical sequence

<220>

<221> misc_feature

<222> (2, 4, 5, 8, 11)..(13)

<223> Xaa = any amino acid

<400> 85

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
1 5 10

<210> 86

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 4, 5, 8, 11)..(13)

<223> Xaa = any amino acid

<400> 86

Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Pro
1 5 10

<210> 87

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 87

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly
20

<210> 88

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 88

Gly Gly Asp Tyr His Cys Arg Met Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Leu Gly Gly
20

<210> 89

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 89

Gly Gly Val Tyr Ala Cys Arg Met Gly Pro Ile Thr Trp Val Cys Ser
1 5 10 15

Pro Leu Gly Gly
20

<210> 90

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 90

Val Gly Asn Tyr Met Cys His Phe Gly Pro Ile Thr Trp Val Cys Arg
 1 5 10 15

Pro Gly Gly Gly
 20

<210> 91

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 91

Gly Gly Leu Tyr Leu Cys Arg Phe Gly Pro Val Thr Trp Asp Cys Gly
 1 5 10 15

Tyr Lys Gly Gly
 20

<210> 92

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 92

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr
 20 25 30

Trp Val Cys Lys Pro Gln Gly Gly
 35 40

<210> 93

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (20)..(20)

<223> Position 20, amino acid linker to an identical sequence

<400> 93

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly
 20

<210> 94

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 94

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10 15

Pro Gln Gly Gly Ser Ser Lys
 20

<210> 95

<211> 46

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 95

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser Lys Gly Gly Thr Tyr Ser Cys His Phe Gly
20 25 30

Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Ser Ser Lys
35 40 45

<210> 96

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (23)..(23)

<223> Position 23, amino acid linker to an identical sequence

<400> 96

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser Lys
20

<210> 97

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (22)..(22)

<223> Position 22 linked through epsilon amine to lysyl, which is linked to a separate identical sequence through that sequence's alpha amine

<400> 97

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser
20

<210> 98

<211> 23

<212> PRT

<213> Artificial sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (23)..(23)

<223> At position 23 biotin linked to the sidechain through a linker

<400> 98

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Ser Ser Lys
20

<210> 99

<211> 5

<212> PRT

<213> Artificial sequence

<220>

<223> G-CSF-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (4)..(4)

<223> At position 4 disulfide bond to residue 4 of a separate identical sequence

<400> 99

Glu Glu Asp Cys Lys
1 5

<210> 100

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> G-CSF-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (4)..(4)

<223> At position 4, Xaa is an isoteric ethylene spacer linked to a separate identical sequence

<400> 100

Glu Glu Asp Xaa Lys
1 5

<210> 101

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> G-CSF-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is a pyroglutamic acid residue

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is an isoteric ethylene spacer linked to a separate identical sequence.

<400> 101

Xaa Gly Glu Asp Xaa Lys
1 5

<210> 102

<211> 5

<212> PRT

<213> Artificial sequence

<220>

<223> G-CSF-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is a picolinic acid residue

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is an isoteric ethylene spacer linked to a separate identical sequence.

<400> 102

Xaa Ser Asp Xaa Lys
1 5

<210> 103

```

<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> G-CSF-MIMETIC PEPTIDE
<220>
<221> misc_feature
<222> (5)..(5)
<223> At position 5, amino acid linker to an identical sequence

<400> 103
Glu Glu Asp Cys Lys
1          5

<210> 104
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> G-CSF-MIMETIC PEPTIDE
<220>
<221> misc_feature
<222> (5)..(5)
<223> At position 5, amino acid linker to an identical sequence

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa = any amino acid

<400> 104
Glu Glu Asp Xaa Lys
1          5

```

<210> 105

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIVIRAL (HBV)

<400> 105

Leu Leu Gly Arg Met Lys
1 5

<210> 106

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 106

Tyr Cys Phe Thr Ala Ser Glu Asn His Cys Tyr
1 5 10

<210> 107

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 107

Tyr Cys Phe Thr Asn Ser Glu Asn His Cys Tyr
1 5 10

<210> 108

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 108

Tyr Cys Phe Thr Arg Ser Glu Asn His Cys Tyr
1 5 10

<210> 109

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 109

Phe Cys Ala Ser Glu Asn His Cys Tyr
1 5

<210> 110

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 110

Tyr Cys Ala Ser Glu Asn His Cys Tyr
1 5

<210> 111

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 111

Phe Cys Asn Ser Glu Asn His Cys Tyr
1 5

<210> 112

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 112

Phe Cys Asn Ser Glu Asn Arg Cys Tyr
1 5

<210> 113

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 113

Phe Cys Asn Ser Val Glu Asn Arg Cys Tyr
1 5 10

<210> 114

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 114

Tyr Cys Ser Gln Ser Val Ser Asn Asp Cys Phe
1 5 10

<210> 115

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 115

Phe Cys Val Ser Asn Asp Arg Cys Tyr
1 5

<210> 116

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 116

Tyr Cys Arg Lys Glu Leu Gly Gln Val Cys Tyr
1 5 10

<210> 117

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 117

Tyr Cys Lys Glu Pro Gly Gln Cys Tyr
1 5

<210> 118

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 118

Tyr Cys Arg Lys Glu Met Gly Cys Tyr
1 5

<210> 119

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 119

Phe Cys Arg Lys Glu Met Gly Cys Tyr
1 5

<210> 120

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 120

Tyr Cys Trp Ser Gln Asn Leu Cys Tyr
1 5

<210> 121

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 121

Tyr Cys Glu Leu Ser Gln Tyr Leu Cys Tyr
1 5 10

<210> 122

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 122

Tyr Cys Trp Ser Gln Asn Tyr Cys Tyr
1 5

<210> 123

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF ANTAGONIST PEPTIDE

<400> 123

Tyr Cys Trp Ser Gln Tyr Leu Cys Tyr
1 5

<210> 124

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Xaa (Pos1) can be C, A, a-amino-g-bromobutyric acid or Hoc.

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa can be R, H, L or W.

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be M, F or I.

<220>

<221> misc_feature

<222> (6)..(6)

<223> Xaa can be any one of the 20 L-amino acids or the stereoisomeric D-amino acids.

<220>

<221> misc_feature

<222> (9)..(9)

<223> Xaa can be D, E, I, L or V.

<220>

<221> misc_feature

<222> (10)..(10)

<223> Xaa can be a-amino-g-bromobutyric acid or Hoc, provided that either Xaa (Pos1) or Xaa (Pos10) is C or Hoc.

<400> 124

Xaa	Xaa	Xaa	Gly	Pro	Xaa	Thr	Trp	Xaa	Xaa
1				5					10

<210> 125

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> CTLA4-MIMETIC

<400> 125

Gly Phe Val Cys Ser Gly Ile Phe Ala Val Gly Val Gly Arg Cys
1 5 10 15

<210> 126

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> CTLA4-MIMETIC

<400> 126

Ala Pro Gly Val Arg Leu Gly Cys Ala Val Leu Gly Arg Tyr Cys
1 5 10 15

<210> 127

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> C3B ANTAGONIST

<400> 127

Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr Ala Gly His
1 5 10 15

Met Ala Asn Leu Thr Ser His Ala Ser Ala Ile
20 25

<210> 128

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> C3B ANTAGONIST

<400> 128

Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr
1 5 10

<210> 129

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> C3B ANTAGONIST

<400> 129

Cys Val Val Gln Asp Trp Gly His His Ala Cys
1 5 10

<210> 130

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 130

Thr Phe Ser Asp Leu Trp
1 5

<210> 131

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 131

Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
1 5 10

<210> 132

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 132

Gln Pro Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
1 5 10

<210> 133

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 133

Gln Glu Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 134

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 134

Gln Pro Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 135

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 135

Met	Pro	Arg	Phe	Met	Asp	Tyr	Trp	Glu	Gly	Leu	Asn
1				5					10		

<210> 136

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 136

Val	Gln	Asn	Phe	Ile	Asp	Tyr	Trp	Thr	Gln	Gln	Phe
1				5					10		

<210> 137

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 137

Thr	Gly	Pro	Ala	Phe	Thr	His	Tyr	Trp	Ala	Thr	Phe
1				5					10		

<210> 138

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 138

Ile	Asp	Arg	Ala	Pro	Thr	Phe	Arg	Asp	His	Trp	Phe	Ala	Leu	Val
1				5					10					15

<210> 139

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 139

Pro Arg Pro Ala Leu Val Phe Ala Asp Tyr Trp Glu Thr Leu Tyr
1 5 10 15

<210> 140

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 140

Pro Ala Phe Ser Arg Phe Trp Ser Asp Leu Ser Ala Gly Ala His
1 5 10 15

<210> 141

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 141

Pro Ala Phe Ser Arg Phe Trp Ser Lys Leu Ser Ala Gly Ala His
1 5 10 15

<210> 142

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 4, 8)..(9)

<223> Xaa = any amino acid

<400> 142

Pro Xaa Phe Xaa Asp Tyr Trp Xaa Xaa Leu
1 5 10

<210> 143

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 143

Gln Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
1 5 10

<210> 144

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 144

Gln Pro Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro
1 5 10

<210> 145

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 145

Gln Glu Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 146

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MDM/HDM ANTAGONIST PEPTIDE

<400> 146

Gln Pro Thr Phe Ser Asp Tyr Trp Lys Leu Leu Pro
1 5 10

<210> 147

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 147

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 148

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 148

Asp Ile Thr Trp Asp Glu Leu Trp Lys Ile Met Asn
 1 5 10

<210> 149

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 149

Asp Tyr Thr Trp Phe Glu Leu Trp Asp Met Met Gln
 1 5 10

<210> 150

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 150

Gln Ile Thr Trp Ala Gln Leu Trp Asn Met Met Lys
 1 5 10

<210> 151

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 151

Asp Met Thr Trp His Asp Leu Trp Thr Leu Met Ser
 1 5 10

<210> 152

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 152

Asp	Tyr	Ser	Trp	His	Asp	Leu	Trp	Glu	Met	Met	Ser
1				5					10		

<210> 153

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 153

Glu	Ile	Thr	Trp	Asp	Gln	Leu	Trp	Glu	Val	Met	Asn
1				5					10		

<210> 154

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 154

His	Val	Ser	Trp	Glu	Gln	Leu	Trp	Asp	Ile	Met	Asn
1				5					10		

<210> 155

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 155

His Ile Thr Trp Asp Gln Leu Trp Arg Ile Met Thr
1 5 10

<210> 156

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 156

Arg Asn Met Ser Trp Leu Glu Leu Trp Glu His Met Lys
1 5 10

<210> 157

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 157

Ala Glu Trp Thr Trp Asp Gln Leu Trp His Val Met Asn Pro Ala Glu
1 5 10 15

Ser Gln

<210> 158

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 158

His Arg Ala Glu Trp Leu Ala Leu Trp Glu Gln Met Ser Pro
 1 5 10

<210> 159

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 159

Lys Lys Glu Asp Trp Leu Ala Leu Trp Arg Ile Met Ser Val
 1 5 10

<210> 160

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 160

Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
 1 5 10

<210> 161

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 161

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
 1 5 10

<210> 162

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 162

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 163

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 163

Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys
1 5 10

<210> 164

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 164

Ser Cys Val Lys Trp Gly Lys Lys Glu Phe Cys Gly Ser
1 5 10

<210> 165

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 165

Ser Cys Trp Lys Tyr Trp Gly Lys Glu Cys Gly Ser
1 5 10

<210> 166

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 166

Ser Cys Tyr Glu Trp Gly Lys Leu Arg Trp Cys Gly Ser
1 5 10

<210> 167

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 167

Ser Cys Leu Arg Trp Gly Lys Trp Ser Asn Cys Gly Ser
1 5 10

<210> 168

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 168

Ser Cys Trp Arg Trp Gly Lys Tyr Gln Ile Cys Gly Ser
1 5 10

<210> 169
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 169

Ser Cys Val Ser Trp Gly Ala Leu Lys Leu Cys Gly Ser
 1 5 10

<210> 170
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 170

Ser Cys Ile Arg Trp Gly Gln Asn Thr Phe Cys Gly Ser
 1 5 10

<210> 171
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 171

Ser Cys Trp Gln Trp Gly Asn Leu Lys Ile Cys Gly Ser
 1 5 10

<210> 172
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 172

Ser Cys Val Arg Trp Gly Gln Leu Ser Ile Cys Gly Ser
1 5 10

<210> 173

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 173

Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu Lys Gly Ala Ile Leu Thr
1 5 10 15

Thr Met Leu Ala Lys
20

<210> 174

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 174

Arg Arg Trp Lys Lys Asn Phe Ile Ala Val Ser Ala Ala Asn Arg Phe
1 5 10 15

Lys Lys

<210> 175

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 175

Arg Lys Trp Gln Lys Thr Gly His Ala Val Arg Ala Ile Gly Arg Leu
1 5 10 15

Ser Ser

<210> 176

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 176

Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
1 5 10

<210> 177

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 177

Lys Ile Trp Ser Ile Leu Ala Pro Leu Gly Thr Thr Leu Val Lys Leu
1 5 10 15

Val Ala

<210> 178

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 178

Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu
1 5 10

<210> 179

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 179

Leu Lys Trp Lys Lys Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Lys
1 5 10 15

Leu Leu

<210> 180

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 180

Ala Glu Trp Pro Ser Leu Thr Glu Ile Lys Thr Leu Ser His Phe Ser
1 5 10 15

Val

<210> 181

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 181

Ala Glu Trp Pro Ser Pro Thr Arg Val Ile Ser Thr Thr Tyr Phe Gly
1 5 10 15

Ser

<210> 182

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 182

Ala Glu Leu Ala His Trp Pro Pro Val Lys Thr Val Leu Arg Ser Phe
1 5 10 15

Thr

<210> 183

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 183

Ala Glu Gly Ser Trp Leu Gln Leu Leu Asn Leu Met Lys Gln Met Asn
1 5 10 15

Asn

<210> 184

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> CALMODULIN ANTAGONIST PEPTIDE

<400> 184

Ala	Glu	Trp	Pro	Ser	Leu	Thr	Glu	Ile	Lys
1				5					10

<210> 185

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 185

Ser	Thr	Gly	Gly	Phe	Asp	Asp	Val	Tyr	Asp	Trp	Ala	Arg	Gly	Val	Ser
1				5					10					15	

Ser	Ala	Leu	Thr	Thr	Thr	Leu	Val	Ala	Thr	Arg
			20					25		

<210> 186

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 186

Ser	Thr	Gly	Gly	Phe	Asp	Asp	Val	Tyr	Asp	Trp	Ala	Arg	Arg	Val	Ser
1				5					10					15	

Ser	Ala	Leu	Thr	Thr	Thr	Leu	Val	Ala	Thr	Arg
			20					25		

<210> 187

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 187

Ser Arg Gly Val Asn Phe Ser Glu Trp Leu Tyr Asp Met Ser Ala Ala
 1 5 10 15

Met Lys Glu Ala Ser Asn Val Phe Pro Ser Arg Arg Ser Arg
 20 25 30

<210> 188

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 188

Ser Ser Gln Asn Trp Asp Met Glu Ala Gly Val Glu Asp Leu Thr Ala
 1 5 10 15

Ala Met Leu Gly Leu Leu Ser Thr Ile His Ser Ser Ser Arg
 20 25 30

<210> 189

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 189

Ser Ser Pro Ser Leu Tyr Thr Gln Phe Leu Val Asn Tyr Glu Ser Ala
 1 5 10 15

Ala Thr Arg Ile Gln Asp Leu Leu Ile Ala Ser Arg Pro Ser Arg
 20 25 30

<210> 190

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 190

Ser Ser Thr Gly Trp Val Asp Leu Leu Gly Ala Leu Gln Arg Ala Ala
1 5 10 15

Asp Ala Thr Arg Thr Ser Ile Pro Pro Ser Leu Gln Asn Ser Arg
20 25 30

<210> 191

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> VINCULIN-BINDING

<400> 191

Asp Val Tyr Thr Lys Lys Glu Leu Ile Glu Cys Ala Arg Arg Val Ser
1 5 10 15

Glu Lys

<210> 192

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> C4BP-BINDING

<400> 192

Glu Lys Gly Ser Tyr Tyr Pro Gly Ser Gly Ile Ala Gln Phe His Ile
1 5 10 15

Asp Tyr Asn Asn Val Ser
20

<210> 193
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> C4BP-BINDING
<400> 193

Ser Gly Ile Ala Gln Phe His Ile Asp Tyr Asn Asn Val Ser Ser Ala
1 5 10 15

Glu Gly Trp His Val Asn
20

<210> 194
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> C4BP-BINDING
<400> 194

Leu Val Thr Val Glu Lys Gly Ser Tyr Tyr Pro Gly Ser Gly Ile Ala
1 5 10 15

Gln Phe His Ile Asp Tyr Asn Asn Val Ser Ser Ala Glu Gly Trp His
20 25 30

Val Asn

<210> 195
<211> 14
<212> PRT
<213> Artificial Sequence

<220>

<223> C4BP-BINDING

<400> 195

Ser Gly Ile Ala Gln Phe His Ile Asp Tyr Asn Asn Val Ser
1 5 10

<210> 196

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 196

Ala Glu Pro Met Pro His Ser Leu Asn Phe Ser Gln Tyr Leu Trp Tyr
1 5 10 15

Thr

<210> 197

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 197

Ala Glu His Thr Tyr Ser Ser Leu Trp Asp Thr Tyr Ser Pro Leu Ala
1 5 10 15

Phe

<210> 198

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 198

Ala Glu Leu Asp Leu Trp Met Arg His Tyr Pro Leu Ser Phe Ser Asn
1 5 10 15

Arg

<210> 199

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 199

Ala Glu Ser Ser Leu Trp Thr Arg Tyr Ala Trp Pro Ser Met Pro Ser
1 5 10 15

Tyr

<210> 200

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 200

Ala Glu Trp His Pro Gly Leu Ser Phe Gly Ser Tyr Leu Trp Ser Lys
1 5 10 15

Thr

<210> 201

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 201

Ala Glu Pro Ala Leu Leu Asn Trp Ser Phe Phe Phe Asn Pro Gly Leu
1 5 10 15

His

<210> 202

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 202

Ala Glu Trp Ser Phe Tyr Asn Leu His Leu Pro Glu Pro Gln Thr Ile
1 5 10 15

Phe

<210> 203

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 203

Ala Glu Pro Leu Asp Leu Trp Ser Leu Tyr Ser Leu Pro Pro Leu Ala
1 5 10 15

Met

<210> 204

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 204

Ala Glu Pro Thr Leu Trp Gln Leu Tyr Gln Phe Pro Leu Arg Leu Ser
1 5 10 15

Gly

<210> 205

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 205

Ala Glu Ile Ser Phe Ser Glu Leu Met Trp Leu Arg Ser Thr Pro Ala
1 5 10 15

Phe

<210> 206

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 206

Ala Glu Leu Ser Glu Ala Asp Leu Trp Thr Thr Trp Phe Gly Met Gly
1 5 10 15

Ser

<210> 207

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 207

Ala Glu Ser Ser Leu Trp Arg Ile Phe Ser Pro Ser Ala Leu Met Met
1 5 10 15

Ser

<210> 208

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 208

Ala Glu Ser Leu Pro Thr Leu Thr Ser Ile Leu Trp Gly Lys Glu Ser
1 5 10 15

Val

<210> 209

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 209

Ala Glu Thr Leu Phe Met Asp Leu Trp His Asp Lys His Ile Leu Leu
1 5 10 15

Thr

<210> 210
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE
 <400> 210

Ala Glu Ile Leu Asn Phe Pro Leu Trp His Glu Pro Leu Trp Ser Thr
 1 5 10 15

Glu

<210> 211
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> UKR ANTAGONIST PEPTIDE
 <400> 211

Ala Glu Ser Gln Thr Gly Thr Leu Asn Thr Leu Phe Trp Asn Thr Leu
 1 5 10 15

Arg

<210> 212
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>

<221> misc_feature

<222> (1)..(1)

<223> Xaa is V, L, I, E, P, G, Y, M, T or D.

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa is Y, W or F.

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa is F, W or Y.

<220>

<221> misc_feature

<222> (5)..(5)

<223> Xaa is P or Azetidine.

<220>

<221> misc_feature

<222> (7)..(7)

<223> Xaa is S, A, V or L.

<220>

<221> misc_feature

<222> (8)..(8)

<223> Xaa is V, L, I or E.

<220>

<221> misc_feature

<222> (9)..(9)

<223> Xaa is Q or P.

<400> 212

Xaa Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
1 5

<210> 213

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 213

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 214

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 214

Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser
1 5 10 15

Gly Leu

<210> 215

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 215

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 216

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 216

Glu Asn Thr Tyr Ser Pro Asn Trp Ala Asp Ser Met Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 217

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 217

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 218

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 218

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 219

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 219

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 220

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 220

Phe Glu Trp Thr Pro Gly Tyr Trp Gln His Tyr
1 5 10

<210> 221

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 221

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 222

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, optionally acetlated at N terminus

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 222

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 223

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa = azetidine

<400> 223

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Pro	Tyr	Gln	Xaa	Tyr
1				5					10		

<210> 224

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 224

Phe	Ala	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 225

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 225

Phe	Glu	Trp	Ala	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 226

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 226

Phe	Glu	Trp	Val	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 227

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 227

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 228
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, optionally acetylated at N terminus

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa = azetidine

<400> 228
 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 229
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, Xaa products = "MeGly"

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 229

Phe	Glu	Trp	Thr	Pro	Xaa	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 230

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa = MeGly

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 230

Phe	Glu	Trp	Thr	Pro	Xaa	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 231

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 231

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr
1 5 10

<210> 232

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 232

Phe Glu Trp Thr Pro Gly Trp Trp Gln Pro Tyr
1 5 10

<210> 233

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 233

Phe Glu Trp Thr Pro Asn Tyr Trp Gln Pro Tyr
1 5 10

<210> 234

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = pipecolic acid

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 234

Phe	Glu	Trp	Thr	Xaa	Val	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 235

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = pipecolic acid

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 235

Phe	Glu	Trp	Thr	Xaa	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 236

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa = Aib

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 236

Phe	Glu	Trp	Thr	Pro	Xaa	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 237

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = MeGly

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 237

Phe	Glu	Trp	Thr	Xaa	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 238

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, amino group added at C terminus

<400> 238

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro	Tyr
1				5					10	

<210> 239

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, amino group added at C-terminus

<400> 239

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	His	Tyr
1				5					10	

<210> 240

<211> 11
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue
 Position 11 amino group added at C-terminus

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 240

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 241

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 optionally acetylated at N-terminus

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 241

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 242

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (8)..(8)

<223> Position 8, Xaa is a phyosphotyrosyl residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 242

A-527.ST25.txt

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Xaa	Gln	Xaa	Tyr
1				5					10	

<210> 243
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 243

Phe	Ala	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 244
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 244

Phe	Glu	Trp	Ala	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 245

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 245

Phe	Glu	Trp	Val	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 246

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 246

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 247

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 acetylated at N-terminus

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 247

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 248

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 248

Phe	Glu	Trp	Thr	Pro	Ala	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 249

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is a sarcosine residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 249

Phe	Glu	Trp	Thr	Pro	Xaa	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 250

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 250

A-527.ST25.txt

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Pro	Tyr
1				5					10	

<210> 251
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 251

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Trp	Gln	Pro	Tyr
1				5					10	

<210> 252
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 252

Phe	Glu	Trp	Thr	Pro	Asn	Tyr	Trp	Gln	Pro	Tyr
1				5					10	

<210> 253
 <211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 253

Phe	Glu	Trp	Thr	Pro	Val	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 254

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a pipecolic acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 254

Phe	Glu	Trp	Thr	Xaa	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 255

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa = pipecolic acid

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 255

Phe	Glu	Trp	Thr	Pro	Xaa	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 256

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = MeGly

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 256

Phe	Glu	Trp	Thr	Xaa	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 257

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 257

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10					15

<210> 258

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, xaa is a 1-naphthylalanine residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 258

xaa	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 259

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 259

Tyr Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 260
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> Position 11 amino group added at C-terminus

<400> 260

Phe Glu Trp Val Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 261
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 261

Phe	Glu	Trp	Thr	Pro	Ser	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 262

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11 amino group added at C-terminus

<400> 262

Phe Glu Trp Thr Pro Asn Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 263

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 263

Thr Lys Pro Arg
1

<210> 264

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 264

Arg Lys Ser Ser Lys
1 5

<210> 265

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 265

Arg Lys Gln Asp Lys
1 5

<210> 266

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 266

Asn Arg Lys Gln Asp Lys
1 5

<210> 267

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 267

Arg Lys Gln Asp Lys Arg
1 5

<210> 268

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 268

Glu Asn Arg Lys Gln Asp Lys Arg Phe
1 5

<210> 269
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 269
 Val Thr Lys Phe Tyr Phe
 1 5

<210> 270
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 270
 Val Thr Lys Phe Tyr
 1 5

<210> 271
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 271
 Val Thr Asp Phe Tyr
 1 5

<210> 272
 <211> 17
 <212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 272

Ser Gly Ser Gly Val Leu Lys Arg Pro Leu Pro Ile Leu Pro Val Thr
1 5 10 15

Arg

<210> 273

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 273

Arg Trp Leu Ser Ser Arg Pro Leu Pro Pro Leu Pro Leu Pro Pro Arg
1 5 10 15

Thr

<210> 274

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 274

Gly Ser Gly Ser Tyr Asp Thr Leu Ala Leu Pro Ser Leu Pro Leu His
1 5 10 15

Pro Met Ser Ser
20

<210> 275

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 275

Gly Ser Gly Ser Tyr Asp Thr Arg Ala Leu Pro Ser Leu Pro Leu His
1 5 10 15

Pro Met Ser Ser
20

<210> 276

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 276

Gly Ser Gly Ser Ser Gly Val Thr Met Tyr Pro Lys Leu Pro Pro His
1 5 10 15

Trp Ser Met Ala
20

<210> 277

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 277

Gly Ser Gly Ser Ser Gly Val Arg Met Tyr Pro Lys Leu Pro Pro His
1 5 10 15

Trp Ser Met Ala
20

<210> 278

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/ PROTEASE INHIBITOR PEPTIDE

<400> 278

Gly Ser Gly Ser Ser Ser Met Arg Met Val Pro Thr Ile Pro Gly Ser
1 5 10 15

Ala Lys His Gly
20

<210> 279

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTI-HBV

<400> 279

Leu Leu Gly Arg Met Lys
1 5

<210> 280

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTI-HBV

<400> 280

Ala Leu Leu Gly Arg Met Lys Gly
1 5

<210> 281

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTI-HBV

<400> 281

Leu Asp Pro Ala phe Arg
1 5

<210> 282

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 282

Arg Pro Leu Pro Pro Leu Pro
1 5

<210> 283

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 283

Arg Glu Leu Pro Pro Leu Pro
1 5

<210> 284

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 284

Ser Pro Leu Pro Pro Leu Pro
1 5

<210> 285

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 285

Gly Pro Leu Pro Pro Leu Pro
1 5

<210> 286

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 286

Arg Pro Leu Pro Ile Pro Pro
1 5

<210> 287

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 287

Arg Pro Leu Pro Ile Pro Pro
1 5

<210> 288
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE
 <400> 288
 Arg Arg Leu Pro Pro Thr Pro
 1 5

<210> 289
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE
 <400> 289
 Arg Gln Leu Pro Pro Thr Pro
 1 5

<210> 290
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE
 <400> 290
 Arg Pro Leu Pro Ser Arg Pro
 1 5

<210> 291
 <211> 7
 <212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 291

Arg Pro Leu Pro Thr Arg Pro
1 5

<210> 292

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 292

Ser Arg Leu Pro Pro Leu Pro
1 5

<210> 293

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 293

Arg Ala Leu Pro Ser Pro Pro
1 5

<210> 294

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 294

Arg Arg Leu Pro Arg Thr Pro
1 5

<210> 295

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 295

Arg Pro Val Pro Pro Ile Thr
1 5

<210> 296

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 296

Ile Leu Ala Pro Pro Val Pro
1 5

<210> 297

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 297

Arg Pro Leu Pro Met Leu Pro
1 5

<210> 298

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 298

Arg Pro Leu Pro Ile Leu Pro
1 5

<210> 299

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 299

Arg Pro Leu Pro Ser Leu Pro
1 5

<210> 300

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 300

Arg Pro Leu Pro Ser Leu Pro
1 5

<210> 301

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 301

Arg Pro Leu Pro Met Ile Pro
1 5

<210> 302

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 302

Arg Pro Leu Pro Leu Ile Pro
1 5

<210> 303

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 303

Arg Pro Leu Pro Pro Thr Pro
1 5

<210> 304

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 304

Arg Ser Leu Pro Pro Leu Pro
1 5

<210> 305

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 305

Arg Pro Gln Pro Pro Pro Pro
1 5

<210> 306

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<400> 306

Arg Gln Leu Pro Ile Pro Pro
1 5

<210> 307

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1, 2, 3)..(11)

<223> Xaa = any amino acid

<400> 307

Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro
 1 5 10

<210> 308

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1, 2, 3, 11)..(12)

<223> Xaa = any amino acid

<400> 308

Xaa Xaa Xaa Arg Pro Leu Pro Pro Ile Pro Xaa Xaa
 1 5 10

<210> 309

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1, 2, 3, 11,)..(12)

<223> Xaa = any amino acid

<400> 309

Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Xaa
 1 5 10

<210> 310

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 3, 10)..(11)

<223> Xaa = any amino acid

<400> 310

Arg	Xaa	Xaa	Arg	Pro	Leu	Pro	Pro	Leu	Pro	Xaa	Pro
1				5					10		

<210> 311

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2)..(3)

<223> Xaa = any amino acid

<400> 311

Arg	Xaa	Xaa	Arg	Pro	Leu	Pro	Pro	Leu	Pro	Pro	Pro
1				5					10		

<210> 312

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(12)

<223> Xaa = any amino acid

<400> 312

Pro Pro Pro Tyr Pro Pro Pro Pro Ile Pro Xaa Xaa
1 5 10

<210> 313

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (11)..(12)

<223> Xaa = any amino acid

<400> 313

Pro Pro Pro Tyr Pro Pro Pro Pro Val Pro Xaa Xaa
1 5 10

<210> 314

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 3)..(8)

<223> Xaa (Pos2, 3, 8) is any amino acid

<220>

<221> misc_feature

<222> (9)..(9)

<223> Xaa (Pos 9) represents an aliphatic amino acid residue

<400> 314

Leu	Xaa	Xaa	Arg	Pro	Leu	Pro	Xaa	Xaa	Pro
1				5					10

<210> 315

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is an aliphatic amino acid residue

<220>

<221> misc_feature

<222> (2, 3)..(8)

<223> Positions 2, 3 & 8, Xaa is any amino acid

<400> 315

Xaa	Xaa	Xaa	Arg	Pro	Leu	Pro	Xaa	Leu	Pro
1				5					10

<210> 316

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa is any amino acid residue

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is an aromatic amino acid residue

<220>

<221> misc_feature

<222> (9)..(9)

<223> Position 9, Xaa is an aliphatic amino acid residue

<400> 316

Pro	Pro	Xaa	Xaa	Tyr	Pro	Pro	Pro	Xaa	Pro
1				5					10

<210> 317

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is a basic amino acid residue

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is an aliphatic amino acid residue

<220>

<221> misc_feature

<222> (6)..(9)

<223> Positions 6 & 9, Xaa is any amino acid residue

<400> 317

Xaa	Pro	Pro	Xaa	Pro	Xaa	Lys	Pro	Xaa	Trp	Leu
1				5					10	

<210> 318

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3, 4)..(6)

<223> Positions 3, 4 & 6, Xaa is an aliphatic amino acid residue

<220>

<221> misc_feature

<222> (8)..(8)

<223> Position 8, Xaa is a basic amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is any amino acid residue

<400> 318

Arg	Pro	Xaa	Xaa	Pro	Xaa	Arg	Xaa	Ser	Xaa	Pro
1				5					10	

<210> 319

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (8)..(9)

<223> Xaa = any amino acid

<400> 319

Pro	Pro	Val	Pro	Pro	Arg	Pro	Xaa	Xaa	Thr	Leu
1				5					10	

<210> 320

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> SH3 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1, 3)..(6)

<223> Positions 1, 3 and 6, Xaa is an aliphatic amino acid residue

<400> 320

Xaa	Pro	Xaa	Leu	Pro	Xaa	Lys
1				5		

<210> 321
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SH3 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is a basic amino acid residue

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> Position 2, Xaa is an aromatic amino acid residue

<220>
 <221> misc_feature
 <222> (4)..(8)
 <223> Positions 4 & 8, Xaa is any amino acid residue

<400> 321
 Xaa Xaa Asp Xaa Pro Leu Pro Xaa Leu Pro
 1 5 10

<210> 322
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> INHIBITION OF PLATELET AGGREGATION
 <220>

<221> misc_feature
 <222> (2)..(3)
 <223> Xaa = any amino acid

<400> 322
 Cys Xaa Xaa Arg Gly Asp Cys
 1 5

<210> 323
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SRC ANTAGONIST
 <400> 323
 Arg Pro Leu Pro Pro Leu Pro
 1 5

<210> 324
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SRC ANTAGONIST
 <400> 324
 Pro Pro Val Pro Pro Arg
 1 5

<210> 325
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTI-CANCER (PARTICULARLY FOR SARCOMAS)
 Page 143

<220>

<221> misc_feature

<222> (1, 3, 5, 7, 8, 10)..(11)

<223> xaa = any amino acid

<400> 325

Xaa Phe Xaa Asp Xaa Trp Xaa Xaa Leu Xaa Xaa
1 5 10

<210> 326

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 326

Lys Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser
1 5 10 15

Arg Asp Cys Asp
20

<210> 327

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 327

Arg Glu Arg Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly
1 5 10 15

Asp Phe Ala Trp
20

<210> 328

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 328

Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg
1 5 10 15

Leu Ile Phe Ser
20

<210> 329

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 329

Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser
1 5 10 15

Lys Arg Lys Pro
20

<210> 330

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 330

Arg Arg Leu Ile Phe
1 5

<210> 331

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 331

Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg
1 5 10 15

Leu Ile Phe Ser Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met
20 25 30

Lys Trp Lys Lys
35

<210> 332

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> P16-MIMETIC

<400> 332

Lys Arg Arg Leu Ile Phe Ser Lys Arg Gln Ile Lys Ile Trp Phe Gln
1 5 10 15

Asn Arg Arg Met Lys Trp Lys Lys
20

<210> 333

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> PREFERRED LINKER

<400> 333

Gly Gly Gly Lys Gly Gly Gly Gly
1 5

<210> 334

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> PREFERRED LINKER

<400> 334

Gly Gly Gly Asn Gly Ser Gly Gly
1 5

<210> 335

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> PREFERRED LINKER

<400> 335

Gly Gly Gly Cys Gly Gly Gly Gly
1 5

<210> 336

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> PREFERRED LINKER

<400> 336

Gly Pro Asn Gly Gly
1 5

<210> 337

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC

<220>

<221> misc_feature

<222> (1)..(1)

<223> Fc domain attached at Position 1 of the N-terminus

<400> 337

Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
1 5 10 15

Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr
20 25 30

Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 338

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC

<220>

<221> misc_feature

<222> (41)..(41)

<223> Fc domain attached at Position 41 of the C-terminus

<400> 338

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala Gly Gly Gly Gly Gly
35 40

<210> 339
 <211> 49
 <212> PRT
 <213> Artificial Sequence

<220>

<223> EPO-MIMETIC

<220>

<221> misc_feature

<222> (1)..(1)

<223> Fc domain attached at Position 1 of the N-terminus

<400> 339

Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu
 1 5 10 15

Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Thr
 20 25 30

Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly
 35 40 45

Gly

<210> 340
 <211> 49
 <212> PRT
 <213> Artificial Sequence

<220>

<223> EPO-MIMETIC

<220>

<221> misc_feature

<222> (49)..(49)

<223> Fc domain attached at Position 49 of the C-terminus

<400> 340

A-527.ST25.txt

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe
20 25 30

Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly
35 40 45

Gly

<210> 341

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 341

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Ile Glu
1 5 10 15

Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 342

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 342

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Ile
1 5 10 15

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25

<210> 343

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 343

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 344

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 344

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 345

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 345

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 346

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 346

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
20 25 30

Ala

<210> 347

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 347

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala
20 25 30

Arg Ala

<210> 348

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 348

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
20 25 30

Ala Arg Ala
35

<210> 349

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 349

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 350

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 350

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
20 25 30

Leu Ala Ala Arg Ala
35

<210> 351

<211> 38

<212> PRT

<213> Artificial Sequence

<220> .

<223> TPO-MIMETIC PEPTIDES

<400> 351

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln
20 25 30

Trp Leu Ala Ala Arg Ala -
35

<210> 352

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 352

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
20 25 30

Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 353

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 353

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Pro
1 5 10 15

Asn Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
20 25 30

<210> 354

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 354

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 355

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 355

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 356

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 356

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 357

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 357

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 358

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<220>

<221> misc_feature

<222> (19)..(19)

<223> Position 19, Xaa = bromoacetyl

<400> 358

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
20 25 30

Leu Ala Ala Arg Ala
35

<210> 359

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 359

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 360

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<220>

<221> misc_feature

<222> (19)..(19)

<223> Position 19, Xaa = Poly(ethylene glycol)

<400> 360

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
20 25 30

Leu Ala Ala Arg Ala
35

<210> 361

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<220>

<221> misc_feature

<222> (19)..(19)

<223> Position 19, Xaa = Poly(ethylene glycol)

<400> 361

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Xaa Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
20 25 30

Leu Ala Ala Arg Ala
35

<210> 362

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 362

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15
 Gly Asn Gly Ser Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30
 Ala Ala Arg Ala
 35

<210> 363

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC PEPTIDES

<400> 363

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
 1 5 10 15
 Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 20 25 30
 Ala Ala Arg Ala
 35

<210> 364

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-TMP

<400> 364
aaaaaaggat cctcgagatt aagcacgagc agccagccac tgacgcagag tcggacc 57

<210> 365

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-TMP

<400> 365
aaaggtggag gtggtggtat cgaaggtccg actctgcgt 39

<210> 366

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-TMP

<400> 366
cagtggctgg ctgctcgtgc ttaatctcga ggatcctttt tt 42

<210> 367

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-TMP

<220>

<221> CDS

<222> (1)..(60)

<223>

<400> 367
aaa ggt gga ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg 48
Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu

1 5 15 81
gct gct cgt gct taatctcgag gacccctttt t
Ala Ala Arg Ala
20

<210> 368
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> FC-TMP
<400> 368
Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
1 5 10 15

Ala Ala Arg Ala
20

<210> 369
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> FC-TMP
<400> 369
aacataagta cctgtaggat cg 22

<210> 370
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> FC-TMP
<400> 370
ttcgatacca ccacctccac ctttaccgag agacagggag aggctcttct gc 52

<210> 371

<211> 60
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-TMP-TMP

<400> 371
 aaaggtggag gtggtggtat cgaaggtccg actctgcgtc agtggctggc tgctcgtgct 60

<210> 372
 <211> 48
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-TMP-TMP

<400> 372
 acctccacca ccagcacgag cagccagcca ctgacgcaga gtcggacc 48

<210> 373
 <211> 66
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fc-TMP-TMP

<400> 373
 ggtggtggag gtggcggcgg aggtattgag ggcccaaccc ttcgccaatg gcttgcagca 60
 cgcgca 66

<210> 374
 <211> 76
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Fc-TMP-TMP

<400> 374

Ala Ala Ala Ala Ala Ala Ala Gly Gly Ala Thr Cys Cys Thr Cys Gly
 1 5 10 15

Ala Gly Ala Thr Thr Ala Thr Gly Cys Gly Cys Gly Thr Gly Cys Thr
 20 25 30

Gly Cys Ala Ala Gly Cys Cys Ala Thr Thr Gly Gly Cys Gly Ala Ala
 35 40 45

Gly Gly Gly Thr Thr Gly Gly Gly Cys Cys Cys Thr Cys Ala Ala Thr
 50 55 60

Ala Cys Cys Thr Cys Cys Gly Cys Cys Gly Cys Cys
 65 70 75

<210> 375

<211> 126

<212> DNA

<213> Artificial sequence

<220>

<223> FC-TMP-TMP

<220>

<221> CDS

<222> (1)..(126)

<223>

<400> 375
 aaa ggt gga ggt ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg 48
 Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
 1 5 10 15

gct gct cgt gct ggt ggt gga ggt ggc ggc gga ggt att gag ggc cca 96
 Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
 20 25 30

acc ctt cgc caa tgg ctt gca gca cgc gca 126
 Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
 35 40

<210> 376

<211> 42

<212> PRT

<213> Artificial sequence

<220>

<223> Fc-TMP-TMP

<400> 376

Lys Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
1 5 10 15

Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro
20 25 30

Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala
35 40

<210> 377

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 377

Thr Thr Thr Thr Thr Thr Cys Ala Thr Ala Thr Gly Ala Thr Cys Gly
1 5 10 15

Ala Ala Gly Gly Thr Cys Cys Gly Ala Cys Thr Cys Thr Gly Cys Gly
20 25 30

Thr Cys Ala Gly Thr Gly Gly
35

<210> 378

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 378

Ala Gly Cys Ala Cys Gly Ala Gly Cys Ala Gly Cys Cys Ala Gly Cys
1 5 10 15

Cys Ala Cys Thr Gly Ala Cys Gly Cys Ala Gly Ala Gly Thr Cys Gly
20 25 30

Gly Ala Cys Cys Thr Thr Cys Gly Ala Thr Cys Ala Thr Ala Thr Gly
35 40 45

<210> 379

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 379

ctggctgctc gtgctggtgg aggcggtggg gacaaaactc acaca

45

<210> 380

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 380

ctggctgctc gtgctggcgg tgggtggcggg ggggggtggca ttgagggccc a

51

<210> 381

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 381

aagccattgg cgaagggttg ggccctcaat gccaccccct ccgccaccac cgcc

54

<210> 382

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 382
acccttcgcc aatggcttgc agcacgcgca gggggaggcg gtggggacaa aact 54

<210> 383

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 383
cccaccgcct ccccctgcgc gtgctgc 27

<210> 384

<211> 189

<212> DNA

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<220>

<221> CDS

<222> (10)..(180)

<223>

<400> 384
ttttttcat atg atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt 51
Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg
1 5 10

gct ggc ggt ggt ggc gga ggg ggt ggc att gag ggc cca acc ctt cgc 99
Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
15 20 25 30

caa tgg ctg gct gct cgt gct ggt gga ggc ggt ggg gac aaa act ctg 147
Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Asp Lys Thr Leu
35 40 45

gct gct cgt gct ggt gga ggc ggt ggg gac aaa actcacaca
 Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys
 50 55

<210> 385

<211> 57

<212> PRT

<213> Artificial Sequence

<220>

<223> TMP-TMP-Fc

<400> 385

Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly
 1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
 20 25 30

Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr Leu Ala Ala
 35 40 45

Arg Ala Gly Gly Gly Gly Gly Asp Lys
 50 55

<210> 386

<211> 141

<212> DNA

<213> Artificial Sequence

<220>

<223> pAMG21

<400> 386

ctaattccgc tctcacctac caaacaatgc cccctgcaa aaaataaatt catataaaaa 60

acatacagat aaccatctgc ggtgataaat tatctctggc ggtgttgaca taaataccac 120

tggcggatgat actgagcaca t 141

<210> 387

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> pAMG21

<400> 387

cgatttgatt ctagaaggag gaataacata tggttaacgc gttggaattc ggtac 55

<210> 388

<211> 872

<212> DNA

<213> Artificial Sequence

<220>

<223> GM221

<400> 388

ttattttcgt gcggccgcac cattatcacc gccagaggta aactagtcaa cacgcacggt	60
gtagatatt tatcccttgc ggtgatagat tgagcacatc gatttgattc tagaaggagg	120
gataatatat gagcacaanaa aagaaaccat taacacaaga gcagcttgag gacgcacgtc	180
gccttaaagc aatttatgaa aaaaagaaaa atgaacttgg cttatcccag gaatctgtcg	240
cagacaagat ggggatgggg cagtcaggcg ttggtgcttt atttaatggc atcaatgcat	300
taaatgctta taacgccgca ttgcttaca aaattctcaa agttagcggt gaagaattta	360
gcccttcaat cgccagagaa tctacgagat gtatgaagcg gttagtatgc agccgtcact	420
tagaagtgag tatgagtacc ctgttttttc tcatgttcag gcagggatgt tctcacctaa	480
gcttagaacc tttaccaaag gtgatgcgga gagatgggta agcacaacca aaaaagccag	540
tgattctgca ttctggcttg aggttgaagg taattccatg accgcaccaa caggctccaa	600
gccaagcttt cctgacggaa tgttaattct cgttgaccct gagcaggctg ttgagccagg	660
tgatttctgc atagccagac ttgggggtga tgagtttacc ttcaagaaac tgatcaggga	720
tagcggtcag gtgtttttac aaccactaaa cccacagtac ccaatgatcc catgcaatga	780
gagttgttcc gttgtgggga aagttatcgc tagtcagtgg cctgaagaga cgtttggtg	840
atagactagt ggatccacta gtgtttctgc cc	872

<210> 389

<211> 1197

<212> DNA

<213> Artificial Sequence

<220>

<223> GM221

A-527.ST25.txt

<400> 389
ggcggaaacc gacgtccatc gaatggtgca aaacctttcg cggtatggca tgatagcgcc 60
cggaagagag tcaattcagg gtggtgaatg tgaaaccagt aacgttatac gatgtcgag 120
agtatgccgg tgtctcttat cagaccgttt cccgcgtggt gaaccaggcc agccacgttt 180
ctgcgaaaac gcgggaaaaa gtcgaagcgg cgatggcgga gctgaattac attcccaacc 240
gcgtggcaca acaactggcg ggcaaacagt cgctcctgat tggcgttgcc acctccagtc 300
tggccctgca cgcgccgtcg caaattgtcg cggcgattaa atctcgcgcc gatcaactgg 360
gtgccagcgt ggtggtgtcg atggtagaac gaagcggcgt cgaagcctgt aaagcggcgg 420
tgcacaatct tctcgcgcaa cgcgtcagtg ggctgatcat taactatccg ctggatgacc 480
aggatgccat tgctgtggaa gctgcctgca ctaatgttcc ggcgttatatt cttgatgtct 540
ctgaccagac acccatcaac agtattattt tctcccatga agacggtagc cgactgggcg 600
tggagcatct ggtcgcattg ggtcaccagc aaatcgcgct gttagcgggc ccattaagtt 660
ctgtctcggc gcgtctgcgt ctggctggct ggcataaata tctcactcgc aatcaaattc 720
agccgatagc ggaacgggaa ggcgactgga gtgccatgtc cggttttcaa caaacatgc 780
aaatgctgaa tgagggcatc gttcccactg cgatgctggt tgccaacgat cagatggcgc 840
tgggcgcaat gcgcgccatt accgagtccg ggctgcgcgt tgggtgcggat atctcggtag 900
tgggatacga cgataccgaa gacagctcat gttatatccc gccgttaacc accatcaaac 960
aggattttcg cctgctgggg caaaccagcg tggaccgctt gctgcaactc tctcagggcc 1020
aggcggtgaa gggcaatcag ctggtgcccc tctcactggt gaaaagaaaa accaccctgg 1080
cgcccaatac gcaaaccgcc tctccccgcg cgttggccga ttcattaatg cagctggcac 1140
gacaggtttc ccgactggaa agcggacagt aaggtaccat aggatccagg cacagga 1197

<210> 390

<211> 61

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP

<400> 390
tatgaaagggt ggagggtggtg gtggagggtac ttactcttgc cacttcggcc cgctgacttg 60
g 61

<210> 391

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP

<400> 391
cggtttgcaa acccaagtca gcgggccgaa gtggcaagag taagtacctc caccaccacc 60
tccacctttc at 72

<210> 392

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP

<400> 392
gtttgcaaac cgcaggggtgg cggcggcggc ggcggtggta cctattcctg tcatttt 57

<210> 393

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP

<400> 393
ccaggtcagc gggccaaaat gacaggaata ggtaccaccg ccgccgccgc cgccaccctg 60

<210> 394

<211> 118

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP

<220>

<221> CDS

<222> (2)..(118)

<223>

<400> 394

t	atg	aaa	ggt	gga	ggt	ggt	ggt	gga	ggt	act	tac	tct	tgc	cac	ttc	ggc	49
Met	Lys	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Thr	Tyr	Ser	Cys	His	Phe	Gly	
1				5						10					15		

ccg	ctg	act	tgg	gtt	tgc	aaa	ccg	cag	ggt	ggc	ggc	ggc	ggc	ggc	ggc	ggt	97
Pro	Leu	Thr	Trp	Val	Cys	Lys	Pro	Gln	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	
			20					25					30				

ggt	acc	tat	tcc	tgt	cat	ttt											118
Gly	Thr	Tyr	Ser	Cys	His	Phe											
		35															

<210> 395

<211> 39

<212> PRT

<213> Artificial sequence

<220>

<223> FC-EMP

<400> 395

Met	Lys	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Thr	Tyr	Ser	Cys	His	Phe	Gly
1				5						10					15	

Pro	Leu	Thr	Trp	Val	Cys	Lys	Pro	Gln	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly
			20					25					30			

Gly	Thr	Tyr	Ser	Cys	His	Phe										
		35														

<210> 396

<211> 61

<212> DNA

<213> Artificial sequence

<220>

<223> FC-EMP

<400> 396

gcagaagagc	ctctccctgt	ctccgggtaa	aggtggaggt	ggtggtggag	gtacttactc	60
------------	------------	------------	------------	------------	------------	----

t						61
---	--	--	--	--	--	----

<210> 397
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Fc-EMP

<400> 397
 ctaattggat ccacgagatt aaccaccctg cggtttgcaa 40

<210> 398
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Fc-EMP

<400> 398
 Gly Glu Arg Trp Cys Phe Asp Gly Pro Leu Thr Trp Val Cys Gly Glu
 1 5 10 15

Glu Ser

<210> 399
 <211> 61
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Fc-EMP

<400> 399
 agagtaagta cctccaccac cacctccacc ttacccgga gacagggaga ggctcttctg 60
 c 61

<210> 400
 <211> 61
 <212> DNA

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 400

ggcccgctga cctgggtatg taagccacaa gggggtgggg gaggcggggg gtaatctcga 60
g 61

<210> 401

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 401

gatcctcgag attaccccc gcctcccca ccccttggtg gcttacatac 50

<210> 402

<211> 118

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-Fc

<220>

<221> CDS

<222> (1)..(108)

<223>

<400> 402

ggt tgc aaa ccg cag ggt ggc ggc ggc ggc ggc ggc ggt ggt acc tat tcc 48
Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser 15

tgt cat ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg 96
Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly 20 25 30

gga ggc ggg ggg taatctcgag 118
Gly Gly Gly Gly

35

<210> 403

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 403

Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser
 1 5 10 15

Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly
 20 25 30

Gly Gly Gly Gly
 35

<210> 404

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 404

ttatttcata tgaaaggtgg taactattcc tgtcatttt

39

<210> 405

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 405

tggacatgtg tgagttttgt cccccccgcc tccccacccc cct

43

<210> 406

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 406

agggggtggg ggaggcgggg gggacaaaac tcacacatgt cca

43

<210> 407

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-Fc

<400> 407

gttattgctc agcggtggca

20

<210> 408

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<400> 408

ttttttatcg atttgattct agatttgagt ttttaactttt agaaggagga ataaaatatg

60

<210> 409

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<400> 409

taaaagttaa aactcaaadc tagaatcaaa tcgataaaaa a 41

<210> 410

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<400> 410

ggaggtactt actcttgcca cttcggcccg ctgacttggg ttgcaaacc g 51

<210> 411

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<400> 411

agtcagcggg ccgaagtggc aagagtaagt acctccata tttattcct ccttc 55

<210> 412

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-Fc

<400> 412

caggggtggcg gcggcggcgg cggtggtacc tattcctgtc attttggccc gctgacctgg 60

<210> 413

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-FC

<400> 413
aaaatgacag gaataggtac caccgccgcc gccgccgcca ccctgcggtt tgcaaaccga 60

<210> 414

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-FC

<400> 414
gtatgtaagc cacaaggggg tgggggaggg gggggggaca aaactcacac atgtcca 57

<210> 415

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-FC

<400> 415
agttttgtcc ccccgccctc cccaccccc ttgtggctta catacccagg tcagcgggcc 60

<210> 416

<211> 228

<212> DNA

<213> Artificial Sequence

<220>

<223> EMP-EMP-FC

<220>

<221> CDS

<222> (58)..(228)

<223>

<400> 416

```

ttttttatcg atttgattct agatttgagt tttaactttt agaaggagga ataaaat      57
atg gga ggt act tac tct tgc cac ttc ggc ccg ctg act tgg gtt tgc      105
Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1          5          10          15

aaa ccg cag ggt ggc ggc ggc ggc ggc ggt ggt acc tat tcc tgt cat      153
Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
20          25          30

ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg gga ggc      201
Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
35          40          45

ggg ggg gac aaa act cac aca tgt cca      228
Gly Gly Asp Lys Thr His Thr Cys Pro
50          55

```

<210> 417

<211> 57

<212> PRT

<213> Artificial Sequence

<220>

<223> EMP-EMP-FC

<400> 417

```

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1          5          10          15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His
20          25          30

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
35          40          45

Gly Gly Asp Lys Thr His Thr Cys Pro
50          55

```

<210> 418

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-EMP-EMP

<400> 418

ctaattggat cctcgagatt aacccccttg tggcttacat

40

<210> 419
 <211> 16
 <212> PRT
 <213> Artificial sequence

 <220>
 <223> EPO-MIMETIC PEPTIDE
 <220>
 <221> misc_feature
 <222> (1, 3, 9, 14, 15)..(16)
 <223> Xaa (Positions 1, 3, 9, 14, 15 & 16) can be any one of the 20 L-amino acids

 <220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Xaa can be R, H, L or W

 <220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Xaa can be M, F or I

 <220>
 <221> misc_feature
 <222> (12)..(12)
 <223> Xaa can be D, E, I, L or V

 <220>
 <221> misc_feature
 <222> (13)..(13)
 <223> Xaa can be C, A, α -amino- γ -bromobutyric acid or Hoc

 <400> 419

Xaa Tyr Xaa Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa
 1 5 10 15

<210> 420

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1, 3, 5, 6, 9, 12, 14, 15)..(16)

<223> Xaa = any amino acid residue

<400> 420

Xaa Tyr Xaa Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys Xaa Xaa Xaa
 1 5 10 15

<210> 421

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa can be R, H, L, or W

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be M, F, or I

<220>

<221> misc_feature

<222> (6)..(6)

<223> xaa is independently selected from any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids

<220>

<221> misc_feature

<222> (9)..(9)

<223> Xaa can be D, E, I, L, or V.

<400> 421

Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys
1 5 10

<210> 422

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 422

Gly Gly Thr Tyr Ser Cys His Gly Pro Leu Thr Trp Val Cys Lys Pro
1 5 10 15

Gln Gly Gly

<210> 423

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 423

Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg
Page 181

1

5

15

Pro Gly Gly

<210> 424

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 424

Gly Gly Pro His His Val Tyr Ala Cys Arg Met Gly Pro Leu Thr Trp
1 5 10 15

Ile Cys

<210> 425

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 425

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln

<210> 426

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 426

Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln
1 5 10 15

Pro Leu Arg Gly
20

<210> 427

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 427

Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys
1 5 10 15

Arg Pro Ser Pro Lys Ala
20

<210> 428

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 428

Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10

<210> 429

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 429

Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10

<210> 430

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 430

Ala Glu Pro Val Tyr Gln Tyr Glu Leu Asp Ser Tyr Leu Arg Ser Tyr
1 5 10 15

Tyr

<210> 431

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 431

Ala Glu Leu Asp Leu Ser Thr Phe Tyr Asp Ile Gln Tyr Leu Leu Arg
1 5 10 15

Thr

<210> 432

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 432

Ala Glu Phe Phe Lys Leu Gly Pro Asn Gly Tyr Val Tyr Leu His Ser
1 5 10 15

Ala

<210> 433

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (4, 5)..(6)

<223> Xaa = any amino acid

<400> 433

Phe Lys Leu Xaa Xaa Xaa Gly Tyr Val Tyr Leu
1 5 10

<210> 434

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<400> 434

Ala Glu Ser Thr Tyr His His Leu Ser Leu Gly Tyr Met Tyr Thr Leu
1 5 10 15

Asn

<210> 435

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> UKR ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3, 5)..(6)

<223> Xaa = any amino acid

<400> 435

Tyr His Xaa Leu Xaa Xaa Gly Tyr Met Tyr Thr
1 5 10

<210> 436

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

<400> 436

Arg Asn Arg Gln Lys Thr
1 5

<210> 437

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

<400> 437

Arg Asn Arg Gln
1

<210> 438

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

<400> 438

Arg Asn Arg Gln Lys
1 5

<210> 439

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

<400> 439

Asn Arg Gln Lys Thr
1 5

<210> 440

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> MAST CELL ANTAGONISTS/PROTEASE INHIBITOR PEPTIDE

<400> 440

Arg Gln Lys Thr
1

<210> 441

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (2, 5)..(7)

<223> Xaa = any amino acid

<400> 441

Arg Xaa Glu Thr Xaa Trp Xaa
1 5

<210> 442

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (2, 5)..(7)

<223> Xaa = any amino acid

<400> 442

Arg Xaa Glu Thr Xaa Trp Xaa
1 5

<210> 443

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (5)..(6)

<223> xaa = any amino acid

<400> 443

Arg Gly Asp Gly Xaa
1 5

<210> 444

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> xaa = any amino acid

<400> 444

Cys Arg Gly Asp Gly Xaa Cys
1 5

<210> 445

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (2, 3, 4, 8, 9, 10, 11, 12, 13)..(14)

<223> xaa = any amino acid

<400> 445

A-527.ST25.txt

Cys Xaa Xaa Xaa Arg Leu Asp Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10 15

<210> 446

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 446

Cys Ala Arg Arg Leu Asp Ala Pro Cys
1 5

<210> 447

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 447

Cys Pro Ser Arg Leu Asp Ser Pro Cys
1 5

<210> 448

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (1, 2, 3, 7, 8)..(9)

<223> Xaa are capable of forming a cyclizing bond

<220>

<221> misc_feature

<222> (2)..(5)

<223> Feature at 1, 5 is an amino acid capable of forming a cyclizing bond and attached to 1-5 amino acid linker

<400> 448

Xaa Xaa Xaa Arg Gly Asp Xaa Xaa Xaa
1 5

<210> 449

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (2)..(8)

<223> Xaa = any amino acid

<400> 449

Cys Xaa Cys Arg Gly Asp Cys Xaa Cys
1 5

<210> 450

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 450

Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> 451

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 451

Cys Asp Cys Arg Gly Asp Cys Leu Cys
 1 5

<210> 452

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 452

Cys Leu Cys Arg Gly Asp Cys Ile Cys
 1 5

<210> 453

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (1, 2, 5, 6, 7)..(8)

<223> Xaa = any amino acid

<400> 453

Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa
 1 5

```

<210> 454
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> INTEGRIN-BINDING PEPTIDE
<220>
<221> misc_feature
<222> (1, 2, 3, 6, 7, 8, 9)..(10)
<223> Xaa = any amino acid

<400> 454
Xaa Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa Xaa
1          5          10

<210> 455
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> INTEGRIN-BINDING PEPTIDE
<400> 455
Cys Trp Asp Asp Gly Trp Leu Cys
1          5

<210> 456
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> INTEGRIN-BINDING PEPTIDE
<400> 456

```

Cys Trp Asp Asp Leu Trp Trp Leu Cys
1 5

<210> 457

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 457

Cys Trp Asp Asp Gly Leu Met Cys
1 5

<210> 458

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 458

Cys Trp Asp Asp Gly Trp Met Cys
1 5

<210> 459

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 459

Cys Ser Trp Asp Asp Gly Trp Leu Cys
1 5

<210> 460

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 460

Cys Pro Asp Asp Leu Trp Trp Leu Cys
1 5

<210> 461

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (2)..(8)

<223> Xaa can be any of the 20 L-amino acids

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be C, A, α -amino- γ -bromobutyric acid or Hoc

<220>

<221> misc_feature

<222> (4)..(4)

<223> Xaa can be R, H, L or W

<220>

<221> misc_feature

<222> (5)..(5)

<223> Xaa can be M, F or I; Xaa

<220>

<221> misc_feature

<222> (11)..(11)

<223> Xaa can be D, E, I, L or V

<220>

<221> misc_feature

<222> (12)..(12)

<223> Xaa can be C, A, a-amino-y-bromobutyric acid or Hoc; provided that Xaa (Pos3 or 12) is C or Hoc.

<400> 461

Tyr Xaa Xaa Xaa Xaa Gly Pro Xaa Thr Trp Xaa Xaa
1 5 10

<210> 462

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 462

Cys Gln Asn Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Asn Glu
1 5 10 15

<210> 463

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<400> 463

Ala Glu Asn Trp Ala Asp Asn Glu Pro Asn Asn Lys Arg Asn Asn Glu
1 5 10 15

Asp

<210> 464
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE
 <400> 464

Arg Lys Asn Asn Lys Thr Trp Thr Trp Val Gly Thr Lys Lys Ala Leu
 1 5 10 15

Thr Asn Glu

<210> 465
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE
 <400> 465

Lys Lys Ala Leu Thr Asn Glu Ala Glu Asn Trp Ala Asp
 1 5 10

<210> 466
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SELECTIN ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (3)..(15)

<223> Xaa = any amino acid

<400> 466

Cys Gln Xaa Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Xaa Glu
1 5 10 15

<210> 467

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3, 5, 6, 13)..(15)

<223> Xaa = any amino acid

<400> 467

Arg Lys Xaa Asn Xaa Xaa Trp Thr Trp Val Gly Thr Xaa Lys Xaa Leu
1 5 10 15

Thr Glu Glu

<210> 468

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (13)..(15)

<223> Xaa = any amino acid

<400> 468

Ala Glu Asn Trp Ala Asp Gly Glu Pro Asn Asn Lys Xaa Asn Xaa Glu
1 5 10 15

Asp

<210> 469

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 3, 4, 7)..(15)

<223> Xaa = any amino acid

<400> 469

Cys Xaa Xaa Xaa Tyr Thr Xaa Leu Val Ala Ile Gln Asn Lys Xaa Glu
1 5 10 15

<210> 470

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3, 4, 5, 6, 8, 13, 15)..(18)

<223> Xaa = any amino acid

<400> 470

Arg Lys Xaa Xaa Xaa Xaa Trp Xaa Trp Val Gly Thr Xaa Lys Xaa Leu
Page 199

1

5

15

Thr Xaa Glu

<210> 471

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 5, 6, 7, 12, 13)..(14)

<223> Xaa = any amino acid

<400> 471

Ala Xaa Asn Trp Xaa Xaa Xaa Glu Pro Asn Asn Xaa Xaa Xaa Glu Asp
1 5 10 15

<210> 472

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SELECTIN ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1, 3, 6, 9, 12)..(13)

<223> Xaa = any amino acid

<400> 472

Xaa Lys Xaa Lys Thr Xaa Glu Ala Xaa Asn Trp Xaa Xaa
1 5 10

<210> 473

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Xaa is Asp-Arg-Met-Pro-Cys, Arg-Met-Pro-Cys, Met-Pro-Cys, Pro-Cys
or Cys

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa is Arg or Lys

<220>

<221> misc_feature

<222> (10)..(10)

<223> Xaa is Ser or Thr

<220>

<221> misc_feature

<222> (12)..(12)

<223> Xaa is Cys-Lys or Cys

<400> 473

Xaa	Xaa	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Xaa	Ser	Xaa
1				5					10		

<210> 474

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 474

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10 15

Lys

<210> 475

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 475

Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
1 5 10 15

<210> 476

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 476

Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
1 5 10

<210> 477

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 477

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10 15

<210> 478

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 478

Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10

<210> 479

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 479

Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10

<210> 480

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 480

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10 15

<210> 481
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 481

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
 1 5 10 15

<210> 482
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 482

Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
 1 5 10

<210> 483
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE
 <400> 483

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
 1 5 10 15

<210> 484
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 484

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10

<210> 485

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 485

Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 5 10

<210> 486

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 486

Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10 15

Lys

<210> 487

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 487

Met	Pro	Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys	Lys
1				5					10					15

<210> 488

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 488

Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys	Lys
1			5						10			

<210> 489

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 489

Asp	Arg	Met	Pro	Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5					10					15	

<210> 490

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 490

Met	Pro	Cys	Arg	Asn	Phe	Phe	Trp	Lys	Thr	Phe	Thr	Ser	Cys
1				5					10				

<210> 491

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 491

Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

<210> 492

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 492

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10 15

Lys

<210> 493

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 493

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
1 5 10 15

<210> 494

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 494

Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
1 5 10

<210> 495

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 495

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10 15

<210> 496

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 496

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

<210> 497

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> SOMATOSTATIN OR CORTISTATIN MIMETIC PEPTIDE

<400> 497

Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

<210> 498

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> CAP37 MIMETIC/LPS BINDING

<400> 498

Asn Gln Gly Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe
1 5 10 15

Val Met Thr Ala Ala Ser Cys Phe Gln
20 25

<210> 499

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> CAP37 MIMETIC/LPS BINDING

<400> 499

Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe Val Met Thr
1 5 10 15

Ala Ala Ser Cys
20

<210> 500

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> CAP37 MIMETIC/LPS BINDING

<400> 500

Gly Thr Arg Cys Gln Val Ala Gly Trp Gly Ser Gln Arg Ser Gly Gly
1 5 10 15

Arg Leu Ser Arg Phe Pro Arg Phe Val Asn Val
20 25

<210> 501

<211> 18

<212> PRT

<213> Artificial sequence

<220>

<223> VEGF- ANTAGONIST

<400> 501

Gly Glu Arg Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Trp
1 5 10 15

Glu Ile

<210> 502

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF- ANTAGONIST

<400> 502

Glu Glu Leu Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Tyr
1 5 10 15

Val Lys

<210> 503

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 503

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys
1 5 10 15

Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln
20 25 30

Gln

<210> 504

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (7, 18,)..(19)

<223> Positions 7, 18, and 19, D amino acid residue

<400> 504

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys
1 5 10 15

Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln
20 25 30

Glu

<210> 505

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (18)..(19)

<223> Positions 18 and 19, D amino acid residues

<400> 505

Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro	Leu	Phe	Lys
1				5				10						15	

Thr	Leu	Leu	Ser	Ala	Val
			20		

<210> 506

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (7, 18)..(19)

<223> Positions 7, 18 and 19, D amino acid residues

<400> 506

Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro	Leu	Phe	Lys
1				5				10						15	

Thr	Leu	Leu	Ser	Ala	Val
			20		

<210> 507

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (8, 19)..(20)

<223> Positions 8, 19 and 20, D amino acid residues

<400> 507

Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe
 1 5 10 15

Lys Thr Leu Leu Ser Ala Val
 20

<210> 508

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (9, 20)..(21)

<223> Positions 9, 20 and 21, D amino acid residues

<400> 508

Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu
 1 5 10 15

Phe Lys Thr Leu Leu Ser Ala Val
 20

<210> 509

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (9, 20)..(21)

<223> Positions 9, 20 and 21, D amino acid residues

<400> 509

Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu
1 5 10 15

Phe Lys Thr Leu Leu Ser Ala Val
20

<210> 510

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (7)..(7)

<223> Position 7, D amino acid residue

<400> 510

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser
1 5 10

<210> 511

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 511

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20 25

<210> 512

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (5, 8, 17)..(23)

<223> Positions 5, 8, 17 and 23, D amino acid residues

<400> 512

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20 25

<210> 513

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (5, 18, 17)..(23)

<223> Positions 5, 18, 17 and 23, D amino acid residues

<400> 513

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20 25

<210> 514

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (5, 8, 17)..(21)

<223> Positions 5, 8, 17 and 21, D amino acid residues

<400> 514

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg
20

<210> 515

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (2, 5, 14)..(18)

<223> Positions 2, 5, 14 and 18, D amino acid residues

<400> 515

Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu Ile Ser Trp
1 5 10 15

Ile Lys Arg

<210> 516

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (3, 4, 8)..(10)

<223> Positions 3, 4, 8 and 10, D amino acid residues

<400> 516

Lys Leu Leu Leu Leu Leu Lys Leu Leu Leu Leu Lys
1 5 10

<210> 517

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (3, 4, 8)..(10)

<223> Positions 3, 4, 8 and 10, D amino acid residues

<400> 517

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
1 5 10

<210> 518
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE
 <220>
 <221> misc_feature
 <222> (3, 4, 8)..(10)
 <223> Positions 3, 4, 8 and 10, D amino acid residues

<400> 518
 Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
 1 5 10

<210> 519
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE
 <400> 519
 Lys Lys Leu Leu Lys Leu Lys Leu Lys Leu Lys Lys
 1 5 10

<210> 520
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE
 <400> 520

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
 1 5 10

<210> 521
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE
 <400> 521

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
 1 5 10

<210> 522
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE
 <400> 522

Lys Leu Leu Leu Leu Lys
 1 5

<210> 523
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> ANTIPATHOGENIC PEPTIDE
 <400> 523

Lys Leu Leu Leu Lys Leu Leu Lys
 1 5

<210> 524
 <211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 524

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
1 5 10

<210> 525

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 525

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
1 5 10

<210> 526

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 526

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys
1 5 10

<210> 527

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 527

Lys Ala Ala Ala Lys Ala Ala Ala Lys Ala Ala Lys
1 5 10

<210> 528

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 528

Lys Val Val Val Lys Val Val Val Lys Val Val Lys
1 5 10

<210> 529

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 529

Lys Val Val Val Lys Val Lys Val Lys Val Val Lys
1 5 10

<210> 530

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 530

Lys Val Val Val Lys Val Lys Val Lys Val Lys
1 5 10

<210> 531

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 531

Lys Val Val Val Lys Val Lys Val Lys Val Val Lys
1 5 10

<210> 532

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 532

Lys Leu Ile Leu Lys Leu
1 5

<210> 533

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 533

Lys Val Leu His Leu Leu
1 5

<210> 534

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 534

Leu Lys Leu Arg Leu Leu
1 5

<210> 535

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 535

Lys Pro Leu His Leu Leu
1 5

<210> 536

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 536

Lys Leu Ile Leu Lys Leu Val Arg
1 5

<210> 537

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 537

Lys Val Phe His Leu Leu His Leu
1 5

<210> 538

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 538

His Lys Phe Arg Ile Leu Lys Leu
1 5

<210> 539

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 539

Lys Pro Phe His Ile Leu His Leu
1 5

<210> 540

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 540

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
1 5 10

<210> 541

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 541

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
1 5 10

<210> 542

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 542

Lys Ile Ile Ile Lys Ile Lys Ile Lys Ile Ile Lys
1 5 10

<210> 543

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 543

Lys Ile Pro Ile Lys Ile Lys Ile Lys Ile Pro Lys
1 5 10

<210> 544

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 544

Lys Ile Pro Ile Lys Ile Lys Ile Lys Ile Val Lys
1 5 10

<210> 545

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 545

Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
1 5 10

<210> 546

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 546

Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
1 5 10

<210> 547

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 547

Arg Ile Ile Ile Arg Ile Arg Ile Arg Ile Ile Arg
1 5 10

<210> 548
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE
<400> 548

Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg
1 5 10

<210> 549
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE
<400> 549

Arg Ile Ile Val Arg Ile Arg Leu Arg Ile Ile Arg
1 5 10

<210> 550
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> ANTIPATHOGENIC PEPTIDE
<400> 550

Arg Ile Gly Ile Arg Leu Arg Val Arg Ile Ile Arg
1 5 10

<210> 551
<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 551

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg
1 5 10

<210> 552

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 552

Arg Ile Ala Val Lys Trp Arg Leu Arg Phe Ile Lys
1 5 10

<210> 553

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 553

Lys Ile Gly Trp Lys Leu Arg Val Arg Ile Ile Arg
1 5 10

<210> 554

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 554

Lys Lys Ile Gly Trp Leu Ile Ile Arg Val Arg Arg
 1 5 10

<210> 555

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 555

Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg
 1 5 10

<210> 556

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 556

Arg Ile Ile Val Arg Ile Arg Leu Arg Ile Ile Arg Val Arg
 1 5 10

<210> 557

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 557

Arg Ile Gly Ile Arg Leu Arg Val Arg Ile Ile Arg Arg Val
 1 5 10

<210> 558

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 558

Lys Ile Val Ile Arg Ile Arg Ala Arg Leu Ile Arg Ile Arg Ile Arg
1 5 10 15

<210> 559

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 559

Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
1 5 10 15

<210> 560

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 560

Lys Ile Gly Ile Lys Ala Arg Val Arg Ile Ile Arg Val Lys Ile Ile
1 5 10 15

<210> 561

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 561

Arg Ile Ile Val His Ile Arg Leu Arg Ile Ile His His Ile Arg Leu
1 5 10 15

<210> 562

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 562

His Ile Gly Ile Lys Ala His Val Arg Ile Ile Arg Val His Ile Ile
1 5 10 15

<210> 563

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 563

Arg Ile Tyr Val Lys Ile His Leu Arg Tyr Ile Lys Lys Ile Arg Leu
1 5 10 15

<210> 564

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 564

Lys Ile Gly His Lys Ala Arg Val His Ile Ile Arg Tyr Lys Ile Ile
1 5 10 15

<210> 565

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 565

Arg Ile Tyr Val Lys Pro His Pro Arg Tyr Ile Lys Lys Ile Arg Leu
1 5 10 15

<210> 566

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 566

Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys Ile Ile
1 5 10 15

<210> 567

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 567

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg Ile Arg
1 5 10 15

Lys Ile Val

<210> 568

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 568

Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
1 5 10 15

Ile Lys Lys

<210> 569

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 569

Lys Ile Gly Trp Lys Leu Arg Val Arg Ile Ile Arg Val Lys Ile Gly
1 5 10 15

Arg Leu Arg

<210> 570

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 570

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg Ile Arg
1 5 10 15

Lys Ile Val Lys Val Lys Arg Ile Arg
20 25

<210> 571

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 571

Arg Phe Ala Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
1 5 10 15

Ile Lys Lys Ile Arg Lys Arg Val Ile Lys
20 25

<210> 572

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 572

Lys Ala Gly Trp Lys Leu Arg Val Arg Ile Ile Arg Val Lys Ile Gly
1 5 10 15

Arg Leu Arg Lys Ile Gly Trp Lys Lys Arg Val Arg Ile Lys
20 25 30

<210> 573

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 573

Arg Ile Tyr Val Lys Pro His Pro Arg Tyr Ile Lys Lys Ile Arg Leu
1 5 10 15

<210> 574

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 574

Lys Pro Gly His Lys Ala Arg Pro His Ile Ile Arg Tyr Lys Ile Ile
1 5 10 15

<210> 575

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 575

Lys Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg Ile Arg
1 5 10 15

Lys Ile Val

<210> 576

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 576

Arg Ile Ile Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile Arg Leu
1 5 10 15

Ile Lys Lys

<210> 577

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 577

Arg Ile Tyr Val Ser Lys Ile Ser Ile Tyr Ile Lys Lys Ile Arg Leu
1 5 10 15

<210> 578

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 578

Lys Ile Val Ile Phe Thr Arg Ile Arg Leu Thr Ser Ile Arg Ile Arg
1 5 10 15

Ser Ile Val

<210> 579

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 579

Lys Pro Ile His Lys Ala Arg Pro Thr Ile Ile Arg Tyr Lys Met Ile
1 5 10 15

<210> 580

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, disulfide bond to position 26

<220>

<221> misc_feature

<222> (26)..(26)

<223> Position 26, disulfide bond to position 1

<400> 580

Xaa	Cys	Lys	Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro
1				5					10					15	

Leu	Phe	Lys	Thr	Leu	Leu	Ser	Ala	Val	Cys
			20					25	

<210> 581

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 581

Cys	Lys	Lys	Gly	Phe	Phe	Ala	Leu	Ile	Pro	Lys	Ile	Ile	Ser	Ser	Pro
1				5					10					15	

Leu	Phe	Lys	Thr	Leu	Leu	Ser	Ala	Val	Cys
			20					25	

<210> 582

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 582

Cys Lys Lys Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser
 1 5 10 15

Pro Leu Phe Lys Thr Leu Leu Ser Ala Val Cys
 20 25

<210> 583

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, disulfide bond to position 17

<220>

<221> misc_feature

<222> (17)..(17)

<223> Position 17, disulfide bond to position 1

<400> 583

Xaa Cys Arg Ile Val Ile Arg Ile Arg Ile Arg Leu Ile Arg Ile Arg
 1 5 10 15

Cys

<210> 584

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, disulfide bond to position 19

<220>

<221> misc_feature

<222> (19)..(19)

<223> Position 19, disulfide bond to position 1

<400> 584

Xaa	Cys	Lys	Pro	Gly	His	Lys	Ala	Arg	Pro	His	Ile	Ile	Arg	Tyr	Lys
1				5					10					15	

Ile Ile Cys

<210> 585

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, disulfide bond to position 29

<220>

<221> misc_feature

<222> (29)..(29)

<223> Position 29, disulfide bond to position 1

<400> 585

Xaa Cys Arg Phe Ala Val Lys Ile Arg Leu Arg Ile Ile Lys Lys Ile
1 5 10 15

Arg Leu Ile Lys Lys Ile Arg Lys Arg Val Ile Lys Cys
20 25

<210> 586

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 586

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys Cys
1 5 10

<210> 587

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 587

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
1 5 10

<210> 588

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 588

Lys Leu Leu Leu Lys Leu Lys Leu Lys Leu Leu Lys Cys
1 5 10

<210> 589

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> ANTIPATHOGENIC PEPTIDE

<400> 589

Lys Leu Leu Leu Lys Leu Leu Leu Lys Leu Leu Lys
1 5 10

<210> 590

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 590

His Ser Asp Ala Val Phe Tyr Asp Asn Tyr Thr Arg Leu Arg Lys Gln
1 5 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn
20 25

<210> 591

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 591

A-527.ST25.txt

His	Ser	Asp	Ala	Val	Phe	Tyr	Asp	Asn	Tyr	Thr	Arg	Leu	Arg	Lys	Gln
1				5				10						15	

Met	Ala	Val	Lys	Lys	Tyr	Leu	Asn	Ser	Ile	Leu	Asn
			20				25				

```

<210> 592
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<220>
<221> misc_feature
<222> (1)..(1)
<223> Position 1, Xaa is L-Lys, D-Lys or an ornithinyl residue

```

```

<220>
<221> misc_feature
<222> (2)..(2)
<223> Position 2, Xaa is L-Tyr, D-Tyr, Phe, Trp or a p-aminophenylalany
1 residue

```

```

<220>
<221> misc_feature
<222> (3)..(3)
<223> Position 3 is a hydrophobic aliphatic amino acid residue, Positio
n 3, optional attachment to Leu, norleucyl, D-Ala, Asn-Ser, Asn-S
er-Ile-, Asn-Ser-Tyr, Ser-Ile-Leu, Asn-Ser-Tyr-Leu or Asn-Ser-Tyr
-Leu-Asn

```

```

<400> 592
Xaa Xaa Xaa
1

```

```

<210> 593
<211> 5
<212> PRT

```

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(3)

<223> Position 1, Xaa is either absent, a hydrophobic aliphatic residue (X5), X5-Asn, Tyr-X5, Lys-X5, Lys-X5-Asn, Lys-Tyr-X5, Lys-Tyr-X5-Asn, Lys-Lys-Tyr-X5, Lys-Lys-Tyr-X5-Asn, Val-Lys-Lys-Tyr-X5, Val-Ala-Lys-Lys-Tyr-X5-Asn, or Ala-Val-Lys-Lys-Tyr-X5-Asn

<400> 593

Xaa	Ser	Xaa	Leu	Asn
1				5

<210> 594

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1, 5, 6)..(7)

<223> Positions 1 and 6, xaa are cross-linked amino acid residues as defined in w097/40070

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a hydrophobic aliphatic aminod acid residue

<220>

<221> misc_feature

<222> (7)..(7)

<223> Position 7, is a covalent bond or Asn, Ser, Ile, Tyr, Leu, Asn-Ser, Asn-Ser-Ile, Asn-Ser-Tyr, Asn-Ser-Ile-Leu, Asn-Ser-Tyr-Leu, Asn-Ser-Ile-Leu-Asn or Asn-Ser-Tyr-Leu-Asn.

<400> 594

Xaa Lys Lys Tyr Xaa Xaa Xaa
1 5

<210> 595

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 595

Lys Lys Tyr Leu
1

<210> 596

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 596

Asn Ser Ile Leu Asn
1 5

<210> 597

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 597

Lys Lys Tyr Leu
1

<210> 598
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<400> 598

Lys Lys Tyr Ala
1

<210> 599
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<400> 599

Ala Val Lys Lys Tyr Leu
1 5

<210> 600
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<400> 600

Ser Ile Leu Asn
1

<210> 601
<211> 4

<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<400> 601

Lys Lys Tyr Val
1

<210> 602
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<220>
<221> misc_feature
<222> (3)..(3)
<223> Position 3, Xaa is a lauric acid residue

<400> 602
Ser Ile Xaa Asn
1

<210> 603
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<220>
<221> misc_feature
<222> (5)..(5)
<223> Position 5, Xaa is a norleucyl residue

<400> 603

Lys Lys Tyr Leu Xaa
1 5

<210> 604

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 604

Asn Ser Tyr Leu Asn
1 5

<210> 605

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 605

Asn Ser Ile Tyr Asn
1 5

<210> 606

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 606

Lys Lys Tyr Leu Pro Pro Asn Ser Ile Leu Asn
1 5 10

<210> 607
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is a lauric acid residue

<400> 607
 Xaa Lys Lys Tyr Leu
 1 5

<210> 608
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa is a caproic acid residue

<400> 608
 Xaa Lys Lys Tyr Leu
 1 5

<210> 609
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is a norleucyl residue

<400> 609

Lys Lys Tyr Xaa
1

<210> 610

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 610

Val Lys Lys Tyr Leu
1 5

<210> 611

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 611

Leu Asn Ser Ile Leu Asn
1 5

<210> 612

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 612

Tyr Leu Asn Ser Ile Leu Asn
1 5

<210> 613

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 613

Lys Lys Tyr Leu Asn
1 5

<210> 614

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 614

Lys Lys Tyr Leu Asn Ser
1 5

<210> 615

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 615

Lys Lys Tyr Leu Asn Ser Ile
1 5

<210> 616

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 616

Lys Lys Tyr Leu Asn Ser Ile Leu
1 5

<210> 617

<211> 4

<212> PRT

<213> Artificial sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 617

Lys Lys Tyr Leu
1

<210> 618

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 618

Lys Lys Tyr Asp Ala
1 5

<210> 619

<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<400> 619
Ala Val Lys Lys Tyr Leu
1 5

<210> 620
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<400> 620
Asn Ser Ile Leu Asn
1 5

<210> 621
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> VIP-MIMETIC PEPTIDE
<400> 621
Lys Lys Tyr Val
1

<210> 622
<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(3)

<223> Position 3, Xaa is a lauric acid residue

<400> 622

Xaa Ile Xaa Asn
1

<210> 623

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 623

Asn Ser Tyr Leu Asn
1 5

<210> 624

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 624

Asn Ser Ile Tyr Asn
1 5

<210> 625

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a norleucyl residue

<400> 625

Lys Lys Tyr Leu Xaa
1 5

<210> 626

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 626

Lys Lys Tyr Leu Pro Pro Asn Ser Ile Leu Asn
1 5 10

<210> 627

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 627

Lys Lys Tyr Leu
1

<210> 628

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 628

Lys Lys Tyr Asp Ala
1 5

<210> 629

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 629

Ala Val Lys Lys Tyr Leu
1 5

<210> 630

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 630

Asn Ser Ile Leu Asn
1 5

<210> 631

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 631

Lys Lys Tyr Val
1

<210> 632

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(3)

<223> Position 3, Xaa is a lauric acid residue

<400> 632

Xaa Ile Xaa Asn
1

<210> 633

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is a lauric acid residue

<400> 633

Xaa Lys Lys Tyr Leu
1 5

<210> 634

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is a caproic acid residue

<400> 634

Xaa Lys Lys Tyr Leu
1 5

<210> 635

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is a norleucyl residue

<400> 635

Lys Lys Tyr Xaa
1

<210> 636

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 636

Val Lys Lys Tyr Leu
1 5

<210> 637

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 637

Leu Asn Ser Ile Leu Asn
1 5

<210> 638

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 638

Tyr Leu Asn Ser Ile Leu Asn
1 5

<210> 639

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a norleucyl residue

<400> 639

Lys Lys Tyr Leu Xaa
1 5

<210> 640

<211> 5

<212> PRT

<213> Artificial sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 640

Lys Lys Tyr Leu Asn
1 5

<210> 641

<211> 6

<212> PRT

<213> Artificial sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 641

Lys Lys Tyr Leu Asn Ser
1 5

<210> 642

<211> 7

<212> PRT

<213> Artificial sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 642

Lys Lys Tyr Leu Asn Ser Ile
1 5

<210> 643

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 643

Lys Lys Tyr Leu Asn Ser Ile Leu
1 5

<210> 644

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 644

Lys Lys Lys Tyr Leu Asp
1 5

<210> 645

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Positions 1 and 6 disulfide cross-linked

<400> 645

Xaa Cys Lys Lys Tyr Leu Cys
1 5

<210> 646

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<223> Positions 1 and 6 cross-linked by S-CH₂-CO

<400> 646

Cys Lys Lys Tyr Leu Lys
1 5

<210> 647

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<220>

<221> misc_feature

<223> Position 4, D amino acid residue

<400> 647

Lys Lys Tyr Ala
1

<210> 648

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 648

Trp Trp Thr Asp Thr Gly Leu Trp
1 5

<210> 649

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 649

Trp Trp Thr Asp Asp Gly Leu Trp
1 5

<210> 650

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 650

Trp Trp Asp Thr Arg Gly Leu Trp Val Trp Thr Ile
1 5 10

<210> 651

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 651

Phe Trp Gly Asn Asp Gly Ile Trp Leu Glu Ser Gly
 1 5 10

<210> 652

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 652

Asp Trp Asp Gln Phe Gly Leu Trp Arg Gly Ala Ala
 1 5 10

<210> 653

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 653

Arg Trp Asp Asp Asn Gly Leu Trp Val Val Val Leu
 1 5 10

<210> 654

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 654

Ser Gly Met Trp Ser His Tyr Gly Ile Trp Met Gly
 1 5 10

<210> 655

<211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <400> 655

Gly Gly Arg Trp Asp Gln Ala Gly Leu Trp Val Ala
 1 5 10

<210> 656
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <400> 656

Lys Leu Trp Ser Glu Gln Gly Ile Trp Met Gly Glu
 1 5 10

<210> 657
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VIP-MIMETIC PEPTIDE
 <400> 657

Cys Trp Ser Met His Gly Leu Trp Leu Cys
 1 5 10

<210> 658
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 658

Gly	Cys	Trp	Asp	Asn	Thr	Gly	Ile	Trp	Val	Pro	Cys
1				5					10		

<210> 659

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 659

Asp	Trp	Asp	Thr	Arg	Gly	Leu	Trp	Val	Tyr
1				5					10

<210> 660

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 660

Ser	Leu	Trp	Asp	Glu	Asn	Gly	Ala	Trp	Ile
1				5					10

<210> 661

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 661

Lys	Trp	Asp	Asp	Arg	Gly	Leu	Trp	Met	His
1				5					10

<210> 662

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 662

Gln Ala Trp Asn Glu Arg Gly Leu Trp Thr
1 5 10

<210> 663

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 663

Gln Trp Asp Thr Arg Gly Leu Trp Val Ala
1 5 10

<210> 664

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 664

Trp Asn Val His Gly Ile Trp Gln Glu
1 5

<210> 665

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 665

Ser Trp Asp Thr Arg Gly Leu Trp Val Glu
1 5 10

<210> 666

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 666

Asp Trp Asp Thr Arg Gly Leu Trp Val Ala
1 5 10

<210> 667

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 667

Ser Trp Gly Arg Asp Gly Leu Trp Ile Glu
1 5 10

<210> 668

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 668

Glu	Trp	Thr	Asp	Asn	Gly	Leu	Trp	Ala	Leu
1				5					10

<210> 669

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 669

Ser	Trp	Asp	Glu	Lys	Gly	Leu	Trp	Ser	Ala
1				5					10

<210> 670

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VIP-MIMETIC PEPTIDE

<400> 670

Ser	Trp	Asp	Ser	Ser	Gly	Leu	Trp	Met	Asp
1				5					10

<210> 671

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 671

Ser	His	Leu	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln
1				5					10	

<210> 672

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 672

Thr Leu Val Tyr Trp Gln Pro Tyr Ser Leu Gln Thr
1 5 10

<210> 673

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 673

Arg Gly Asp Tyr Trp Gln Pro Tyr Ser Val Gln Ser
1 5 10

<210> 674

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 674

Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 675

<211> 12

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 675

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 676

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 676

Ser Arg Val Trp Phe Gln Pro Tyr Ser Leu Gln Ser
1 5 10

<210> 677

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 677

Asn Met Val Tyr Trp Gln Pro Tyr Ser Ile Gln Thr
1 5 10

<210> 678

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 678

Ser Val Val Phe Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 679

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 679

Thr Phe Val Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 680

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 680

Thr Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg
1 5 10

<210> 681

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 681

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 682

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 682

Ser Pro Val Phe Trp Gln Pro Tyr Ser Ile Gln Ile
1 5 10

<210> 683

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 683

Trp Ile Glu Trp Trp Gln Pro Tyr Ser Val Gln Ser
1 5 10

<210> 684

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 684

Ser Leu Ile Tyr Trp Gln Pro Tyr Ser Leu Gln Met
1 5 10

<210> 685

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 685

Thr Arg Leu Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 686

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 686

Arg Cys Asp Tyr Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 687

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 687

Met Arg Val Phe Trp Gln Pro Tyr Ser Val Gln Asn
1 5 10

<210> 688

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 688

Lys Ile Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 689

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 689

Arg His Leu Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 690

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 690

Ala Leu Val Trp Trp Gln Pro Tyr Ser Glu Gln Ile
1 5 10

<210> 691

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 691

Ser Arg Val Trp Phe Gln Pro Tyr Ser Leu Gln Ser
1 5 10

<210> 692

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 692

Trp Glu Gln Pro Tyr Ala Leu Pro Leu Glu
1 5 10

<210> 693

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 693

Gln Leu Val Trp Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 694

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 694

Asp Leu Arg Tyr Trp Gln Pro Tyr Ser Val Gln Val
1 5 10

<210> 695

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 695

Glu Leu Val Trp Trp Gln Pro Tyr Ser Leu Gln Leu
1 5 10

<210> 696
 <211> 12
 <212> PRT
 <213> Artificial sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 696
 Asp Leu Val Trp Trp Gln Pro Tyr Ser Val Gln Trp
 1 5 10

<210> 697
 <211> 12
 <212> PRT
 <213> Artificial sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 697
 Asn Gly Asn Tyr Trp Gln Pro Tyr Ser Phe Gln Val
 1 5 10

<210> 698
 <211> 12
 <212> PRT
 <213> Artificial sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 698
 Glu Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg
 1 5 10

<210> 699
 <211> 12
 <212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 699

Glu Leu Met Tyr Trp Gln Pro Tyr Ser Val Gln Glu
1 5 10

<210> 700

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 700

Asn Leu Leu Tyr Trp Gln Pro Tyr Ser Met Gln Asp
1 5 10

<210> 701

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 701

Gly Tyr Glu Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 702

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 702

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 703

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 703

Leu Ser Glu Gln Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 704

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 704

Gly Gly Gly Trp Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 705

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 705

Val Gly Arg Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 706

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 706

Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 707

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 707

Gln Ala Arg Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 708

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 708

Val His Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr
1 5 10

<210> 709

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 709

Arg Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 710

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 710

Thr Arg Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 711

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 711

Gly Arg Ile Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 712

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 712

Gly Arg Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 713
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 713
 Ala Arg Thr Trp Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 714
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 714
 Ala Arg Val Trp Trp Gln Pro Tyr Ser Val Gln Met
 1 5 10

<210> 715
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 715
 Arg Leu Met Phe Tyr Gln Pro Tyr Ser Val Gln Arg
 1 5 10

<210> 716
 <211> 12
 <212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 716

Glu Ser Met Trp Tyr Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 717

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 717

His Phe Gly Trp Trp Gln Pro Tyr Ser Val His Met
1 5 10

<210> 718

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 718

Ala Arg Phe Trp Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 719

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 719

Arg Leu Val Tyr Trp Gln Pro Tyr Ala Pro Ile Tyr
1 5 10

<210> 720

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 720

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Tyr Gln Thr
1 5 10

<210> 721

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 721

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Leu Pro Ile
1 5 10

<210> 722

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 722

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Ala
1 5 10

<210> 723

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 723

Ser Arg Val Trp Tyr Gln Pro Tyr Ala Lys Gly Leu
1 5 10

<210> 724

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 724

Ser Arg Val Trp Tyr Gln Pro Tyr Ala Gln Gly Leu
1 5 10

<210> 725

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 725

Ser Arg Val Trp Tyr Gln Pro Tyr Ala Met Pro Leu
1 5 10

<210> 726

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 726

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Val Gln Ala
1 5 10

<210> 727

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 727

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Leu Gly Leu
1 5 10

<210> 728

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 728

Ser Arg Val Trp Tyr Gln Pro Tyr Ala Arg Glu Leu
1 5 10

<210> 729

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 729

Ser Arg Val Trp Tyr Gln Pro Tyr Ser Arg Gln Pro
1 5 10

<210> 730

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 730

Ser Arg Val Trp Tyr Gln Pro Tyr Phe Val Gln Pro
1 5 10

<210> 731

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 731

Glu Tyr Glu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 732

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 732

Ile Pro Glu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 733

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 733

Ser Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 734

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 734

Asp Pro Leu Phe Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 735

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 735

Ser Arg Gln Trp Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 736

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 736

Ile Arg Ser Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 737

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 737

Arg Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 738

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 738

Arg Leu Leu Trp Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 739

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 739

Glu Tyr Arg Trp Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 740

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 740

Asp Ala Tyr Trp Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 741

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 741

Trp Ser Gly Tyr Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 742

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 742

Asn Ile Glu Phe Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 743

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 743

Thr	Arg	Asp	Trp	Val	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 744

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 744

Asp	Ser	Ser	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 745

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 745

Ile	Gly	Asn	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 746

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 746

Asn	Leu	Arg	Trp	Asp	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 747

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 747

Leu Pro Glu Phe Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 748

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 748

Asp Ser Tyr Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 749

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 749

Arg Ser Gln Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 750

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 750

Ala Arg Phe Trp Leu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 751

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 751

Asn Ser Tyr Phe Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 752

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 752

Arg Phe Met Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 753

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 753

Ala His Leu Phe Trp Gln Pro Tyr ser Val Gln Arg
1 5 10

<210> 754

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 754

Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5

<210> 755

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 755

Tyr Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5

<210> 756

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 756

Tyr Phe Gln Pro Tyr Ala Leu Gly Leu
1 5

<210> 757

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 757

Tyr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 758

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 758

Arg Trp Trp Gln Pro Tyr Ala Thr Pro Leu
1 5 10

<210> 759

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 759

Gly Trp Tyr Gln Pro Tyr Ala Leu Gly Phe
1 5 10

<210> 760

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 760

Tyr Trp Tyr Gln Pro Tyr Ala Leu Gly Leu
1 5 10

<210> 761

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 761

Ile Trp Tyr Gln Pro Tyr Ala Met Pro Leu
1 5 10

<210> 762

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 762

Ser Asn Met Gln Pro Tyr Gln Arg Leu Ser
1 5 10

<210> 763

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 763

Thr Phe Val Tyr Trp Gln Pro Tyr Ala Val Gly Leu Pro Ala Ala Glu
1 5 10 15

Thr Ala Cys Asn
20

<210> 764
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE
<400> 764

Thr Phe Val Tyr Trp Gln Pro Tyr Ser Val Gln Met Thr Ile Thr Gly
1 5 10 15

Lys Val Thr Met
20

<210> 765
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE
<220>
<221> misc_feature
<222> (12, 13)..(16)
<223> Xaa = any amino acid

<400> 765
Thr Phe Val Tyr Trp Gln Pro Tyr Ser Ser His Xaa Xaa Val Pro Xaa
1 5 10 15

Gly Phe Pro Leu
20

<210> 766
<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 766

Thr Phe Val Tyr Trp Gln Pro Tyr Tyr Gly Asn Pro Gln Trp Ala Ile
1 5 10 15

His Val Arg His
20

<210> 767

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 767

Thr Phe Val Tyr Trp Gln Pro Tyr Val Leu Leu Glu Leu Pro Glu Gly
1 5 10 15

Ala Val Arg Ala
20

<210> 768

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 768

Thr Phe Val Tyr Trp Gln Pro Tyr Val Asp Tyr Val Trp Pro Ile Pro
1 5 10 15

Ile Ala Gln Val
20

<210> 769

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 769

Gly Trp Tyr Gln Pro Tyr Val Asp Gly Trp Arg
1 5 10

<210> 770

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 770

Arg Trp Glu Gln Pro Tyr Val Lys Asp Gly Trp Ser
1 5 10

<210> 771

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 771

Glu Trp Tyr Gln Pro Tyr Ala Leu Gly Trp Ala Arg
1 5 10

<210> 772

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 772

Gly Trp Trp Gln Pro Tyr Ala Arg Gly Leu
1 5 10

<210> 773

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 773

Leu Phe Glu Gln Pro Tyr Ala Lys Ala Leu Gly Leu
1 5 10

<210> 774

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 774

Gly Trp Glu Gln Pro Tyr Ala Arg Gly Leu Ala Gly
1 5 10

<210> 775

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 775

Ala Trp Val Gln Pro Tyr Ala Thr Pro Leu Asp Glu
 1 5 10

<210> 776

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 776

Met Trp Tyr Gln Pro Tyr Ser Ser Gln Pro Ala Glu
 1 5 10

<210> 777

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 777

Gly Trp Thr Gln Pro Tyr Ser Gln Gln Gly Glu Val
 1 5 10

<210> 778

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 778

Asp Trp Phe Gln Pro Tyr Ser Ile Gln Ser Asp Glu
 1 5 10

<210> 779

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 779

Pro	Trp	Ile	Gln	Pro	Tyr	Ala	Arg	Gly	Phe	Gly
1			5						10	

<210> 780

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 780

Arg	Pro	Leu	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln	Val
1				5					10		

<210> 781

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 781

Thr	Leu	Ile	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln	Ile
1				5					10		

<210> 782

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 782

Arg Phe Asp Tyr Trp Gln Pro Tyr Ser Asp Gln Thr
1 5 10

<210> 783

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 783

Trp His Gln Phe Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 784

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 784

Glu Trp Asp Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Thr Leu Leu
1 5 10 15

Arg

<210> 785

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 785

Trp Glu Gln Asn Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Phe Ala
 1 5 10 15

Asp

<210> 786

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 786

Ser Asp Val Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Leu Glu Met
 1 5 10 15

<210> 787

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 787

Tyr Tyr Asp Gly Val Tyr Trp Gln Pro Tyr Ser Val Gln Val Met Pro
 1 5 10 15

Ala

<210> 788

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 788

Ser Asp Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 789

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 789

Gln Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 790

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 790

Ser Arg Ile Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 791

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 791

Arg Ser Leu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 792

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 792

Thr Ile Ile Trp Glu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 793

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 793

Trp Glu Thr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 794

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 794

Ser Tyr Asp Trp Glu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 795

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 795

Ser Arg Ile Trp Cys Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 796

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 796

Glu Ile Met Phe Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 797

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 797

Asp Tyr Val Trp Gln Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 798

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 798

Met Asp Leu Leu Val Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 799

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 799

Gly	Ser	Lys	Val	Ile	Leu	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10					15

<210> 800

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 800

Arg	Gln	Gly	Ala	Asn	Ile	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10					15

<210> 801

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 801

Gly	Gly	Gly	Asp	Glu	Pro	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10					15

<210> 802

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 802

Ser Gln Leu Glu Arg Thr Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 803

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 803

Glu Thr Trp Val Arg Glu Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 804

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 804

Lys Lys Gly Ser Thr Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 805

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 805

Leu Gln Ala Arg Met Asn Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 806

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 806

Glu Pro Arg Ser Gln Lys Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 807

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 807

Val Lys Gln Lys Trp Arg Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 808

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 808

Leu Arg Arg His Asp Val Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
 1 5 10 15

<210> 809

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 809

Arg Ser Thr Ala Ser Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 810

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 810

Glu Ser Lys Glu Asp Gln Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 811

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 811

Glu Gly Leu Thr Met Lys Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 812

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 812

Glu Gly Ser Arg Glu Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 813

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 813

Val Ile Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 814

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 814

Val Trp Tyr Trp Glu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 815

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 815

Ala Ser Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 816

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 816

Phe Tyr Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 817

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 817

Glu Gly Trp Trp Val Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 818

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 818

Trp Gly Glu Trp Leu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 819

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 819

Asp Tyr Val Trp Glu Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 820

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 820

Ala His Thr Trp Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 821

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 821

Phe Ile Glu Trp Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 822

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 822

Trp Leu Ala Trp Glu Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 823

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 823

Val Met Glu Trp Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 824

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 824

Glu Arg Met Trp Gln Pro Tyr Ala Leu Pro Leu
 1 5 10

<210> 825

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (2, 3, 5)..(6)

<223> Xaa = any amino acid

<400> 825

Asn	Xaa	Xaa	Trp	Xaa	Xaa	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 826

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 826

Trp	Gly	Asn	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 827

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 827

Thr	Leu	Tyr	Trp	Glu	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 828

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 828

Val	Trp	Arg	Trp	Glu	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 829

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 829

Leu Leu Trp Thr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 830

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(6)

<223> xaa = any amino acid

<400> 830

Ser Arg Ile Trp Xaa Xaa Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 831

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 831

Ser Asp Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 832

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(6)

<223> Xaa = any amino acid

<400> 832

Trp	Gly	Tyr	Tyr	Xaa	Xaa	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 833

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 833

Thr	Ser	Gly	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 834

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(6)

<223> Xaa = any amino acid

<400> 834

Val His Pro Tyr Xaa Xaa Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 835

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 835

Glu His Ser Tyr Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 836

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(2)

<223> Xaa = any amino acid

<400> 836

Xaa Xaa Ile Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 837

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 837

Ala Gln Leu His Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 838

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 838

Trp Ala Asn Trp Phe Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 839

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 839

Ser Arg Leu Tyr Ser Gln Pro Tyr Ala Leu Pro Leu
1 5 10

<210> 840

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 840

Gly	Val	Thr	Phe	Ser	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 841

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 841

Ser	Ile	Val	Trp	Ser	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 842

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 842

Ser	Arg	Asp	Leu	Val	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10		

<210> 843

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 843

His	Trp	Gly	His	Val	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln	Asp	Asp	Leu
1				5					10					15	

Gly

<210> 844

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 844

Ser Trp His Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Val Pro
1 5 10 15

Glu

<210> 845

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 845

Trp Arg Asp Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Pro Glu Ser
1 5 10 15

Ala

<210> 846

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 846

Thr Trp Asp Ala Val Tyr Trp Gln Pro Tyr Ser Val Gln Lys Trp Leu
1 5 10 15

Asp

<210> 847
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 847

Thr Pro Pro Trp Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Leu Asp
 1 5 10 15

Pro

<210> 848
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 848

Tyr Trp Ser Ser Val Tyr Trp Gln Pro Tyr Ser Val Gln Ser Val His
 1 5 10 15

Ser

<210> 849
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE

<400> 849

Tyr	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Gly	Leu
1				5					10

<210> 850

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 850

Tyr	Trp	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10

<210> 851

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 851

Glu	Trp	Ile	Gln	Pro	Tyr	Ala	Thr	Gly	Leu
1				5					10

<210> 852

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 852

Asn	Trp	Glu	Gln	Pro	Tyr	Ala	Lys	Pro	Leu
1				5					10

<210> 853

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 853

Ala	Phe	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10

<210> 854

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 854

Phe	Leu	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10

<210> 855

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 855

Val	Cys	Lys	Gln	Pro	Tyr	Leu	Glu	Trp	Cys
1				5					10

<210> 856

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 856

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 857

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 857

Gln Gly Trp Leu Thr Trp Gln Asp Ser Val Asp Met Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 858

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 858

Phe Ser Glu Ala Gly Tyr Thr Trp Pro Glu Asn Thr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 859

<211> 21

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 859

Thr Glu Ser Pro Gly Gly Leu Asp Trp Ala Lys Ile Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 860

<211> 21

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 860

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 861

<211> 21

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 861

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 862

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 862

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 863

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 863

Met Asn Asp Gln Thr Ser Glu Val Ser Thr Phe Pro Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 864

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 864

Ser Trp Ser Glu Ala Phe Glu Gln Pro Arg Asn Leu Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 865

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 865

Gln Tyr Ala Glu Pro Ser Ala Leu Asn Asp Trp Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 866

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 866

Asn Gly Asp Trp Ala Thr Ala Asp Trp Ser Asn Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 867

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 867

Thr His Asp Glu His Ile Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 868

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 868

Met Leu Glu Lys Thr Tyr Thr Thr Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 869

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 869

Trp Ser Asp Pro Leu Thr Arg Asp Ala Asp Leu Tyr Trp Gln Pro Tyr
1 5 10 15

Ala Leu Pro Leu
20

<210> 870

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 870

Ser Asp Ala Phe Thr Thr Gln Asp Ser Gln Ala Met Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 871
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE
<400> 871

Gly Asp Asp Ala Ala Trp Arg Thr Asp Ser Leu Thr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 872
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE
<400> 872

Ala Ile Ile Arg Gln Leu Tyr Arg Trp Ser Glu Met Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 873
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE

<400> 873

Glu Asn Thr Tyr Ser Pro Asn Trp Ala Asp Ser Met Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 874

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 874

Met Asn Asp Gln Thr Ser Glu Val Ser Thr Phe Pro Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 875

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 875

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 876

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 876

Gln Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 877

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 877

Glu Asn Pro Phe Thr Trp Gln Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 878

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 878

Val Thr Pro Phe Thr Trp Glu Asp Ser Asn Val Phe Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 879

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 879

Gln Ile Pro Phe Thr Trp Glu Gln Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 880

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 880

Gln Ala Pro Leu Thr Trp Gln Glu Ser Ala Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 881

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 881

Glu Pro Thr Phe Thr Trp Glu Glu Ser Lys Ala Thr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 882

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 882

Thr Thr Thr Leu Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 883

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 883

Glu Ser Pro Leu Thr Trp Glu Glu Ser Ser Ala Leu Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 884

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 884

Glu Thr Pro Leu Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 885
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 885

Glu Ala Thr Phe Thr Trp Ala Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15
 Tyr Ala Leu Pro Leu
 20

<210> 886
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 886

Glu Ala Leu Phe Thr Trp Lys Glu Ser Thr Ala Tyr Tyr Trp Gln Pro
 1 5 10 15
 Tyr Ala Leu Pro Leu
 20

<210> 887
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 887

Ser Thr Pro Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro Tyr
 1 5 10 15

Ala Leu Pro Leu
20

<210> 888

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 888

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 889

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 889

Lys Ala Pro Phe Thr Trp Glu Glu Ser Gln Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 890

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 890

Ser Thr Ser Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 891

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 891

Asp Ser Thr Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 892

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 892

Tyr Ile Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 893

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 893

Gln Thr Ala Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 894

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 894

Glu Thr Leu Phe Thr Trp Glu Glu Ser Asn Ala Thr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 895

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 895

Val Ser Ser Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
 1 5 10 15

Tyr Ala Leu Pro Leu
 20

<210> 896

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 896

Gln Pro Tyr Ala Leu Pro Leu
1 5

<210> 897

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is a phosphotyrosyl residue

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa is a 1-naphthylalanyl residue

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is an azetidine residue

<400> 897

Xaa Xaa Pro Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10

<210> 898

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 898

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 899

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 899

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 900

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 900

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
Page 340

1

5

15

$\langle 210 \rangle$ 901

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

$\langle 222 \rangle \quad (10) \dots (10)$

<223> Position 10, xaa is an azetidine residue

<400> 901

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 902

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 902

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 903

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (13)..(13)

<223> Position 13, Xaa is an azetidine residue

<400> 903

Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Xaa Tyr Ala Leu
1 5 10 15

Pro Leu

<210> 904

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 904

Ala Asp Val Leu Tyr Trp Gln Pro Tyr Ala Pro Val Thr Leu Trp Val
1 5 10 15

<210> 905

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST

<400> 905

Gly Asp Val Ala Glu Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Thr Ser
1 5 10 15

Leu

<210> 906

<211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <400> 906

Ser Trp Thr Asp Tyr Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Ile Ser
 1 5 10 15

Gly Leu

<210> 907
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (1, 2, 7)..(8)
 <223> Xaa is any amino acid

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> Position 4, Xaa is prolyl or an azetidine residue

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> Position 6, Xaa is S, A, V or L

<400> 907

Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
1 5

<210> 908

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is Y, W or F

<220>

<221> misc_feature

<222> (2, 7)..(8)

<223> Xaa is any amino acid

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is prolyl or an azetidine residue

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is S, A, V or L

<400> 908

Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
1 5

<210> 909

```

<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE
<220>
<221> misc_feature
<222> (1)..(1)
<223> Position 1, Xaa is Y, W or F

<220>
<221> misc_feature
<222> (2)..(2)
<223> Position 2, Xaa is E, F, V, W or Y

<220>
<221> misc_feature
<222> (4)..(4)
<223> Position 4, Xaa is prolyl or an azetidine residue

<220>
<221> misc_feature
<222> (6)..(6)
<223> Position 6, Xaa is S, A, V or L

<220>
<221> misc_feature
<222> (7)..(7)
<223> Position 7, Xaa is M, F, V, R, Q, K, T, S, D, L, I or E

<220>
<221> misc_feature
<222> (8)..(8)

```

<223> Position 8, Xaa is E, L, W, V, H, I, G, A, D, L, Y, N, Q or P

<400> 909

Xaa Xaa Gly Xaa Tyr Xaa Xaa Xaa
1 5

<210> 910

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is V, L, I, E, P, G, Y, M, T or D

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa is Y, W or F

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa is E, F, V, W or Y

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is prolyl or an azetidine residue;

<220>

<221> misc_feature

<222> (7)..(7)

<223> Position 7, Xaa is S, A, V or L

<220>

<221> misc_feature

<222> (8)..(8)

<223> Position 8, Xaa is M, F, V, R, Q, K, T, S, D, L, I or E;

<220>

<221> misc_feature

<222> (9)..(9)

<223> Position 9, Xaa is E, L, W, V, H, I, G, A, D, L, Y, N, Q or P

<400> 910

Xaa Xaa Xaa Gln Xaa Tyr Xaa Xaa Xaa
1 5

<210> 911

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 911

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 912

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Xaa = any amino acid

<400> 912

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 913

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 913

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 914

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 914

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 915

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 915

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10					15

<210> 916

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 916

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5					10					15

<210> 917

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa is A, D, E, F, G, K, Q, S, T, V or Y

<220>
<221> misc_feature
<222> (2)..(2)
<223> Position 2, Xaa is A, D, G, I, N, P, S, T, V or W

<220>
<221> misc_feature
<222> (3)..(3)
<223> Position 3, Xaa is A, D, G, L, N, P, S, T, W or Y

<220>
<221> misc_feature
<222> (4)..(4)
<223> Position 4, Xaa is A, D, E, F, L, N, R, V or Y

<220>
<221> misc_feature
<222> (5)..(5)
<223> Position 5, Xaa is A, D, E, Q, R, S or T

<220>
<221> misc_feature
<222> (6)..(6)
<223> Position 6, Xaa is H, I, L, P, S, T or W

<220>
<221> misc_feature
<222> (7)..(7)
<223> Position 7, Xaa is A, E, F, K, N, Q, R, S or Y;

<220>
<221> misc_feature
<222> (8)..(8)

<223> Position 8, Xaa is D, E, F, Q, R, T or W

<220>

<221> misc_feature

<222> (9)..(9)

<223> Position 9, Xaa is A, D, P, S, T or W

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is A, D, G, K, N, Q, S or T

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa is A, E, L, P, S, T, V or Y

<220>

<221> misc_feature

<222> (12)..(12)

<223> Position 12, Xaa is V, L, I, E, P, G, Y, M, T or D

<220>

<221> misc_feature

<222> (13)..(13)

<223> Position 13, Xaa is Y, W or F

<220>

<221> misc_feature

<222> (14)..(14)

<223> Position 14, Xaa is E, F, V, W or Y

<220>

<221> misc_feature

<222> (16)..(16)

<223> Position 16, Xaa is P or an azetidine residue;

<220>

<221> misc_feature

<222> (18)..(18)

<223> Position 18, Xaa is S, A, V or L

<220>

<221> misc_feature

<222> (19)..(19)

<223> Position 19, Xaa is M, F, V, R, Q, K, T, S, D, L, I or E

<220>

<221> misc_feature

<222> (20)..(20)

<223> Position 20, Xaa is Q or P.

<400> 917

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Xaa
1 5 10 15

Tyr Xaa Xaa Xaa Leu
20

<210> 918

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 918

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu

20

<210> 919

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 919

Ser	Trp	Thr	Asp	Tyr	Gly	Tyr	Trp	Gln	Pro	Tyr	Ala	Leu	Pro	Ile	Ser
1				5					10					15	

Gly Leu

<210> 920

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 920

Glu	Thr	Pro	Phe	Thr	Trp	Glu	Glu	Ser	Asn	Ala	Tyr	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
				20

<210> 921

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 921

Glu	Asn	Thr	Tyr	Ser	Pro	Asn	Trp	Ala	Asp	Ser	Met	Tyr	Trp	Gln	Pro

1

5

15

Tyr Ala Leu Pro Leu
20

<210> 922

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 922

Ser Val Gly Glu Asp His Asn Phe Trp Thr Ser Glu Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 923

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 923

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 924

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 924

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
1 5 10 15

<210> 925

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 925

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 926

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 926

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 927

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 927

Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10

<210> 928

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 928

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr
1 5 10

<210> 929

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 929

Ala Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 930
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 930
 Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 931
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 931
 Phe Glu Ala Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 932
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 932

Phe	Glu	Trp	Ala	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 933

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 933

Phe	Glu	Trp	Thr	Ala	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 934

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 934
 Phe Glu Trp Thr Pro Ala Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 935
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 935
 Phe Glu Trp Thr Pro Gly Ala Trp Gln Xaa Tyr
 1 5 10

<210> 936
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 936

Phe Glu Trp Thr Pro Gly Tyr Ala Gln Xaa Tyr
1 5 10

<210> 937

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 937

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Ala
1 5 10

<210> 938

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 938

Phe Glu Trp Thr Gly Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 939

<211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 5, D amino acid residue
 Position 10, Xaa is an azetidine residue

<400> 939
 Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 940
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (5)..(10)
 <223> Position 10, Xaa is an azetidine residue

<400> 940
 Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 941
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a pipecolic acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 941

Phe	Glu	Trp	Thr	Xaa	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 942

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is an aminoisobutyric acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 942

Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 943

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is a sarcosine residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 943

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr
 1 5 10

<210> 944

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa is a sarcosine residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 944

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr
1 5 .10

<210> 945

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 945

Phe Glu Trp Thr Pro Asn Tyr Trp Gln Xaa Tyr
1 5 10

<210> 946

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, D amino acid residue

<400> 946

Phe	Glu	Trp	Thr	Pro	Val	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 947

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 947

Phe	Glu	Trp	Thr	Val	Pro	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 948

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 948

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 949

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 949

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 950

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, xaa = 1-naphthylalanine

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 950

Xaa	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 951

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, xaa is an azetidine residue

<400> 951

Tyr	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 952

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 952

Phe	Glu	Trp	Val	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 953

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 953

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 954

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 954

Phe	Glu	Trp	Thr	Pro	Ser	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 955

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 955

Phe	Glu	Trp	Thr	Pro	Asn	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 956

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = naphthylalanine

<400> 956

Ser His Leu Tyr Xaa Gln Pro Tyr Ser Val Gln Met
1 5 10

<210> 957

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = naphthylalanine

<400> 957

Thr Leu Val Tyr Xaa Gln Pro Tyr Ser Leu Gln Thr
1 5 10

<210> 958

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = naphthylalanine

<400> 958

Arg Gly Asp Tyr Xaa Gln Pro Tyr Ser Val Gln Ser
1 5 10

<210> 959
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = naphthylalanine

<400> 959

Asn	Met	Val	Tyr	Xaa	Gln	Pro	Tyr	Ser	Ile	Gln	Thr
1				5					10		

<210> 960
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 960

Val	Tyr	Trp	Gln	Pro	Tyr	Ser	Val	Gln
1				5				

<210> 961
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = naphthylalanine

<400> 961

Val Tyr Xaa Gln Pro Tyr Ser Val Gln
1 5

<210> 962

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (7)..(7)

<223> Position 7, Xaa is an azetidine residue

<400> 962

Thr Phe Val Tyr Trp Gln Xaa Tyr Ala Leu Pro Leu
1 5 10

<210> 963

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa = p-benzoyl-L-phenylalanine

<400> 963

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Xaa
1				5					10	

<210> 964

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa = p-benzoyl-L-phenylalanine.

<400> 964

Xaa	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Xaa
1				5					10	

<210> 965

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (8)..(10)

<223> Position 8, Xaa = p-benzoyl-L-phenylalanine
Position 10, Xaa is an azetidine residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue

<400> 965

Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr
1 5 10

<210> 966

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = acetylated Phe

<220>

<221> misc_feature

<222> (8)..(8)

<223> Position 8, Xaa = p-benzoyl-L-phenylalanine

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue.

<400> 966

Phe Glu Trp Thr Pro Gly Tyr Xaa Gln Xaa Tyr
1 5 10

<210> 967

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (7)..(7)

<223> Position 7, Xaa = p-benzoyl-L-phenylalanine

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue.

<400> 967

Phe Glu Trp Thr Pro Gly Xaa Tyr Gln Xaa Tyr
1 5 10

<210> 968

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = acetylated Phe

<220>

<221> misc_feature

<222> (7)..(7)

<223> Position 7, Xaa = p-benzoyl-L-phenylalanine

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue.

<400> 968

Phe	Glu	Trp	Thr	Pro	Gly	Xaa	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 969

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = acetylated Phe

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = p-benzoyl-L-phenylalanine

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue.

<400> 969

Phe	Glu	Xaa	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 970

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = acetylated Phe

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = p-benzoyl-L-phenylalanine

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue.

<400> 970

Phe	Glu	Xaa	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 971
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa = p-benzoyl-L-phenylalanine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> Position 10, Xaa is an azetidine residue.

<400> 971

Xaa	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 972
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IL-1 ANTAGONIST PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Position 1, Xaa = acetylated p-benzoyl-L-phenylalanine

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa is an azetidine residue.

<400> 972

Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 973

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 973

Val Tyr Trp Gln Pro Tyr Ser Val Gln
1 5

<210> 974

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 974

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 975

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = naphthylalanine

<400> 975

Arg Leu Val Tyr Xaa Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 976

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 976

Arg Leu Asp Tyr Trp Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 977

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 977

Arg Leu Val Trp Phe Gln Pro Tyr Ser Val Gln Arg
1 5 10

<210> 978

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 978

Arg Leu Val Tyr Trp Gln Pro Tyr Ser Ile Gln Arg
1 5 10

<210> 979

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = D or Y

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = D or S

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa = S, T or A

<220>

<221> misc_feature

<222> (5)..(5)

<223> Position 5, Xaa = S or W

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa = S or Y

<220>

<221> misc_feature

<222> (7)..(7)

<223> Xaa is any amino acid

<220>

<221> misc_feature

<222> (8)..(8)

<223> Position 8, Xaa = N, S, K, H or W

<220>

<221> misc_feature

<222> (9)..(9)

<223> Position 9, Xaa = F or L

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = D, N, S or L

<220>

<221> misc_feature

<222> (11)..(11)

<223> Position 11, Xaa = L, I, Q, M or A.

<400> 979

Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 980

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 980

Asp Asn Ser Ser Trp Tyr Asp Ser Phe Leu Leu
1 5 10

<210> 981

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 981

Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Ala
1 5 10

<210> 982

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 982

Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu
1 5 10

<210> 983

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 983

Pro Ala Arg Glu Asp Asn Thr Ala Trp Tyr Asp Ser Phe Leu Ile Trp
1 5 10 15

Cys

<210> 984

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 984

Thr Ser Glu Tyr Asp Asn Thr Thr Trp Tyr Glu Lys Phe Leu Ala Ser
1 5 10 15

Gln

<210> 985

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 985

Ser Gln Ile Pro Asp Asn Thr Ala Trp Tyr Gln Ser Phe Leu Leu His
1 5 10 15

Gly

<210> 986

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 986

Ser Pro Phe Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr
1 5 10 15

Tyr

<210> 987

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 987

Glu Gln Ile Tyr Asp Asn Thr Ala Trp Tyr Asp His Phe Leu Leu Ser
1 5 10 15

Tyr

<210> 988

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 988

Thr Pro Phe Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr
1 5 10 15

Tyr

<210> 989

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 989

Thr Tyr Thr Tyr Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Met Ser
1 5 10 15

Tyr

<210> 990

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 990

Thr Met Thr Gln Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Ser
1 5 10 15

Tyr

<210> 991

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 991

Thr Ile Asp Asn Thr Ala Trp Tyr Ala Asn Leu Val Gln Thr Tyr Pro
1 5 10 15

Gln

<210> 992

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 992

Thr Ile Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Ala Gln Tyr Pro
1 5 10 15

Asp

<210> 993

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 993

His Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Thr Tyr Thr
1 5 10 15

Pro

<210> 994

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 994

Ser Gln Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Ser Tyr Lys
1 5 10 15

Ala

<210> 995
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE
<400> 995

Gln Ile Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Leu Gln Tyr Asn
1 5 10 15

Ala

<210> 996
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE
<400> 996

Asn Gln Asp Asn Thr Ala Trp Tyr Glu Ser Phe Leu Leu Gln Tyr Asn
1 5 10 15

Thr

<210> 997
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IL-1 ANTAGONIST PEPTIDE
<400> 997

Thr Ile Asp Asn Thr Ala Trp Tyr Glu Asn Phe Leu Leu Asn His Asn
Page 388

1

5

15

Leu

<210> 998

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 998

His Tyr Asp Asn Thr Ala Trp Tyr Glu Arg Phe Leu Gln Gln Gly Trp
1 5 10 15

His

<210> 999

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 999

Glu Thr Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1000

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1000

Tyr Ile Pro Phe Thr Trp Glu Glu Ser Asn Ala Tyr Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1001

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1001

Asp Gly Tyr Asp Arg Trp Arg Gln Ser Gly Glu Arg Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1002

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1, Xaa = phosphotyrosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa = naphthylalanine

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa = phosphotyrosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, Xaa is an azetidine residue.

<400> 1002

Xaa	Xaa	Xaa	Gln	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5					10	

<210> 1003

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1003

Thr	Ala	Asn	Val	Ser	Ser	Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro
1				5					10					15	

Tyr	Ala	Leu	Pro	Leu
				20

<210> 1004

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1004

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5				10						15

<210> 1005

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1005

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro	Tyr	Ala	Leu	Pro	Leu	Ser
1				5				10						15	

Asp

<210> 1006

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1006

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5				10						15

<210> 1007

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1007

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1008

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1008

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1009

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 1 is acetylated Phe
Position 10, Xaa = azetidine

<400> 1009

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1010

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1010

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr
 1 5 10

<210> 1011

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1011

Phe Glu Trp Thr Pro Ala Tyr Trp Gln Xaa Tyr
 1 5 10

<210> 1012

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1012

Phe	Glu	Trp	Thr	Pro	Ala	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1013

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1013

Phe	Glu	Trp	Thr	Pro	Ala	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1014

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1014

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5					10					15

<210> 1015

<211> 15

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1015

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Xaa	Tyr	Ala	Leu	Pro	Leu
1				5					10					15

<210> 1016

<211> 15

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1016

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr Ala Leu Pro Leu
1 5 10 15

<210> 1017

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<400> 1017

Thr Ala Asn Val Ser Ser Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro
1 5 10 15

Tyr Ala Leu Pro Leu
20

<210> 1018

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<400> 1018

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 1019

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1019

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr
1 5 10

<210> 1020

<211> 11

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine

<400> 1020

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1021

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine.

<400> 1021

Phe	Glu	Trp	Thr	Pro	Ala	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 1022

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine.

<400> 1022

Phe	Glu	Trp	Thr	Pro	Ala	Trp	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 1023

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Position 1 is acetylated Phe

<220>

<221> misc_feature

<222> (6)..(6)

<223> Position 6, D amino acid residue

<220>

<221> misc_feature

<222> (10)..(10)

<223> Position 10, Xaa = azetidine.

<400> 1023

Phe Glu Trp Thr Pro Ala Tyr Tyr Gln Xaa Tyr
1 5 10

<210> 1024

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1024

Gly Gly Leu Tyr Leu Cys Arg Phe Gly Pro Val Thr Trp Asp Cys Gly
1 5 10 15

Tyr Lys Gly Gly
20

<210> 1025

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1025

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly
20

<210> 1026

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1026

Gly Gly Asp Tyr His Cys Arg Met Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Leu Gly Gly
20

<210> 1027

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1027

Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Glu Arg Leu

<210> 1028

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<400> 1028

Cys Thr Thr His Trp Gly Phe Thr Leu Cys
 1 5 10

<210> 1029

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1029

Val Gly Asn Tyr Met Cys His Phe Gly Pro Ile Thr Trp Val Cys Arg
 1 5 10 15

Pro Gly Gly Gly
 20

<210> 1030

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1030

Gly Gly Val Tyr Ala Cys Arg Met Gly Pro Ile Thr Trp Val Cys Ser
 1 5 10 15

Pro Leu Gly Gly
 20

<210> 1031

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF- ANTAGONIST

<400> 1031

Arg Gly Trp Val Glu Ile Cys Ala Ala Asp Asp Tyr Gly Arg Cys Leu
1 5 10 15

Thr Glu Ala Gln
20

<210> 1032

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC

<220>

<221> misc_feature

<222> (1)..(1)

<223> Fc domain attached at Position 1 of the N-terminus

<400> 1032

Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala
1 5 10 15

Ala Arg Ala

<210> 1033

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> TPO-MIMETIC

<220>

<221> misc_feature

<222> (19)..(19)

<223> Fc domain attached at Position 19 of the C-terminus

<400> 1033

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Gly Gly

<210> 1034

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC

<220>

<221> misc_feature

<222> (25)..(25)

<223> Fc domain attached at Position 25 of the C-terminus

<400> 1034

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln Gly Gly Gly Gly Gly Gly Gly
20 25

<210> 1035

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1035

Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg
1 5 10 15

Pro Gly Gly

<210> 1036

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1036

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10 15

Pro Gln

<210> 1037

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1037

Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln
1 5 10 15

Pro Leu Arg Gly
20

<210> 1038

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1038

Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys
 1 5 10 15

Arg Pro Ser Pro Lys Ala
 20

<210> 1039

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1039

Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10

<210> 1040

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1040

Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys
 1 5 10

<210> 1041

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> EPO-MIMETIC PEPTIDE

<400> 1041

Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 1 5 10

<210> 1042
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> EPO-MIMETIC PEPTIDE
 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> Xaa (Pos1) can be any one of the 20 L-amino acids; except Xaa (Pos1) may/may not be Y and Xaa (Pos1) may be any non-naturally occurring aromatic acid analog when Xaa (Pos1) is Y.

 <220>
 <221> misc_feature
 <222> (2)..(8)
 <223> Xaa (Pos2, 8) can be any one of the 20 L-amino acids

 <220>
 <221> misc_feature
 <222> (3)..(3)
 <223> Xaa (Pos3) can be C, A, a-amino-y-bromobutyric acid or Hoc;

 <220>
 <221> misc_feature
 <222> (4)..(4)
 <223> Xaa (Pos4) can be R, H, L or W

 <220>
 <221> misc_feature
 <222> (5)..(5)
 <223> Xaa (Pos5) can be M, F or I

<220>

<221> misc_feature

<222> (10)..(10)

<223> Xaa is any amino acid

<220>

<221> misc_feature

<222> (11)..(11)

<223> Xaa (Pos11) can be D, E, I, L or V

<220>

<221> misc_feature

<222> (12)..(12)

<223> Xaa (Pos12) can be C, A, a-amino-γ-bromobutyric acid or Hoc provided that either Xaa (Pos3, 12) is C or Hoc.

<400> 1042

Xaa	Xaa	Xaa	Xaa	Gly	Pro	Xaa	Thr	Trp	Xaa	Xaa
1				5					10	

<210> 1043

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<220>

<221> misc_feature

<222> (3)..(4)

<223> Xaa = any amino acid

<400> 1043

Asp	Leu	Xaa	Xaa	Leu
1				5

<210> 1044

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1044

Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr Thr Leu
1 5 10

<210> 1045

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-ALPHA INHIBITOR

<220>

<221> misc_feature

<222> (1)..(1)

<223> Fc domain attached at Position 1 of the N-terminus

<400> 1045

Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu
1 5 10 15

Gly His Arg Pro
20

<210> 1046

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-ALPHA INHIBITOR

<220>

<221> misc_feature

<222> (20)..(20)

<223> Fc domain attached at Position 20 of the C-terminus

<400> 1046

Asp Phe Leu Pro His Tyr Lys Asn Thr Ser Leu Gly His Arg Pro Gly
1 5 10 15

Gly Gly Gly Gly
20

<210> 1047

<211> 20

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST

<220>

<221> misc_feature

<222> (1)..(1)

<223> Fc domain attached at Position 1 of the N-terminus

<400> 1047

Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr
1 5 10 15

Ala Leu Pro Leu
20

<210> 1048

<211> 20

<212> PRT

<213> Artificial sequence

<220>

<223> IL-1 ANTAGONIST

<220>

<221> misc_feature

<222> (20)..(20)

<223> Fc domain attached at Position 20 of the C-terminus

<400> 1048

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr Ala Leu Pro Leu Gly
1 5 10 15

Gly Gly Gly Gly
20

<210> 1049

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<220>

<221> misc_feature

<222> (1)..(1)

<223> Fc domain attached at Position 1 of the N-terminus

<400> 1049

Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp Ile His Val Met Trp
1 5 10 15

Glu Trp Glu Cys Phe Glu Arg Leu
20

<210> 1050

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<220>

<221> misc_feature

<222> (24)..(24)

<223> Fc domain attached at Position 24 of the C-terminus

<400> 1050

Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Glu Arg Leu Gly Gly Gly Gly Gly
20

<210> 1051

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<220>

<221> misc_feature

<222> (1)..(1)

<223> Fc domain attached at Position 1 of the N-terminus

<400> 1051

Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly Phe Thr Leu Cys
1 5 10 15

<210> 1052

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<220>

<221> misc_feature

<222> (15)..(15)

<223> Fc domain attached at Position 15 of the C-terminus

<400> 1052

Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly Gly Gly
1 5 10 15

<210> 1053

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1053

Arg Thr Asp Leu Asp Ser Leu Arg Thr Tyr
1 5 10

<210> 1054

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1054

Arg Thr Asp Leu Asp Ser Leu Arg Thr
1 5

<210> 1055

<211> 757

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-TNF-ALPHA INHIBITORS

<220>

<221> CDS

<222> (4)..(747)

<223>

```

<400> 1055
cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc      48
   Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
   1      5      10
ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc      96
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
      20      25      30
ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg      144
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
      35      40      45
agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg      192
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
      50      55      60
gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc      240
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
      65      70      75
acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg      288
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
      80      85      90
aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc      336
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
      100      105      110
ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca      384
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
      115      120      125
cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag      432
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
      130      135      140
gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc      480
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
      145      150      155
gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg      528
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
      160      165      170
cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc      576
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
      180      185      190
acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc      624
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
      195      200      205
gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc      672
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
      210      215      220
ctg tct ccg ggt aaa ggt gga ggt ggt ggt gac ttc ctg ccg cac tac      720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Asp Phe Leu Pro His Tyr
      225      230      235

```

aaa aac acc tct ctg ggt cac cgt ccg taatggatcc
 Lys Asn Thr Ser Leu Gly His Arg Pro
 240 245

<210> 1056

<211> 248

<212> PRT

<213> Artificial Sequence

<220>

<223> FC-TNF-ALPA INHIBITORS

<400> 1056

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190

A-527.ST25.txt

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Asp Phe Leu Pro His Tyr Lys
225 230 235 240

Asn Thr Ser Leu Gly His Arg Pro
245

<210> 1057

<211> 761

<212> DNA

<213> Artificial Sequence

<220>

<223> TNF-ALPHA INHIBITOR-Fc

<220>

<221> CDS

<222> (4)..(747)

<223>

<400> 1057

cat	atg	gac	ttc	ctg	ccg	cac	tac	aaa	aac	acc	tct	ctg	ggt	cac	cgt	48
	Met	Asp	Phe	Leu	Pro	His	Tyr	Lys	Asn	Thr	Ser	Leu	Gly	His	Arg	
	1				5					10					15	

ccg	ggt	gga	ggc	ggt	ggg	gac	aaa	act	cac	aca	tgt	cca	cct	tgc	cca	96
Pro	Gly	Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	
				20					25					30		

gca	cct	gaa	ctc	ctg	ggg	gga	ccg	tca	gtt	ttc	ctc	ttc	ccc	cca	aaa	144
Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	
			35					40					45			

ccc	aag	gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	192
Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	
		50					55					60				

gtg	gtg	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	240
Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	
	65					70					75					

gtg	gac	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	288
Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	
	80				85				90					95		

cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	336
Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	

A-527.ST25.txt

100								105				110				
cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	384
Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	
			115					120					125			
gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	432
Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	
		130					135					140				
ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	480
Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	
	145					150					155					
acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	528
Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	
160					165					170					175	
agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	576
Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	
				180					185					190		
tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	624
Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	
			195					200					205			
tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	672
Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	
		210					215					220				
ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	720
Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	
	225					230					235					
aag	agc	ctc	tcc	ctg	tct	ccg	ggc	aaa	taatggatcc	gcgg						761
Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys								
240					245											

<210> 1058

<211> 248

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-ALPHA INHIBITOR-FC

<400> 1058

Met	Asp	Phe	Leu	Pro	His	Tyr	Lys	Asn	Thr	Ser	Leu	Gly	His	Arg	Pro
1				5					10					15	

Gly	Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala
			20					25					30		

Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro
		35					40					45			

Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val

50

55

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
65 70 75 80

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
85 90 95

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
100 105 110

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
115 120 125

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
130 135 140

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
145 150 155 160

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
165 170 175

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
180 185 190

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
195 200 205

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
210 215 220

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
225 230 235 240

Ser Leu Ser Leu Ser Pro Gly Lys
245

-

<210> 1059

<211> 763

<212> DNA

<213> Artificial Sequence

<220>

<223> FC-IL-1 ANTAGONIST

<220>

<221> CDS

<222> (4)..(747)

<223>

```

<400> 1059
cat atg gac aaa act cac aca tgt cca cct tgt cca gct ccg gaa ctc      48
   Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
   1                    5          10          15

ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc      96
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
                    20          25          30

ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg     144
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
                    35          40          45

agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg     192
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
                    50          55          60

gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc     240
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
                    65          70          75

acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg     288
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
                    80          85          90

aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc     336
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
                    100          105          110

ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca     384
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
                    115          120          125

cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag     432
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
                    130          135          140

gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc     480
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
                    145          150          155

gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg     528
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
                    160          165          170

cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc     576
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
                    180          185          190

acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc     624
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
                    195          200          205

gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc     672
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
                    210          215          220

ctg tct ccg ggt aaa ggt gga ggt ggt ggt ttc gaa tgg acc ccg ggt     720
Leu Ser Pro Gly Lys Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly
                    225          230          235

```

tac tgg cag ccg tac gct ctg ccg ctg taatggatcc ctcgag
 Tyr Trp Gln Pro Tyr Ala Leu Pro Leu
 240 245

<210> 1060

<211> 248

<212> PRT

<213> Artificial Sequence

<220>

<223> FC-IL-1 ANTAGONIST

<400> 1060

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190

A-527.ST25.txt

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220
Ser Pro Gly Lys Gly Gly Gly Gly Gly Phe Glu Trp Thr Pro Gly Tyr
225 230 235 240
Trp Gln Pro Tyr Ala Leu Pro Leu
245

<210> 1061

<211> 757

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST-FC

<220>

<221> CDS

<222> (4)..(747)

<223>

<400> 1061

cat	atg	ttc	gaa	tgg	acc	ccg	ggt	tac	tgg	cag	ccg	tac	gct	ctg	ccg	48
	Met	Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro	Tyr	Ala	Leu	Pro	
	1				5					10					15	
ctg	ggt	gga	ggc	ggt	ggg	gac	aaa	act	cac	aca	tgt	cca	cct	tgc	cca	96
Leu	Gly	Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	
				20					25					30		
gca	cct	gaa	ctc	ctg	ggg	gga	ccg	tca	gtt	ttc	ctc	ttc	ccc	cca	aaa	144
Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	
			35					40					45			
ccc	aag	gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	192
Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	
		50					55					60				
gtg	gtg	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	240
Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	
	65					70					75					
gtg	gac	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	288
Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	
80					85				90					95		
cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	336
Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	

100								105				110				
cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	384
Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	
			115					120					125			
gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	432
Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	
		130					135					140				
ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	480
Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	
	145					150					155					
acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	528
Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	
160					165		-			170					175	
agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	576
Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	
				180					185					190		
tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	624
Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	
			195					200					205			
tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	672
Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	
		210					215					220				
ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	720
Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	
	225					230					235					
aag	agc	ctc	tcc	ctg	tct	ccg	ggt	aaa	taatggatcc							757
Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys								
240					245											

<210> 1062

<211> 248

<212> PRT

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST-FC

<400> 1062

Met	Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10					15	

Gly	Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala
			20					25					30		

Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro
		35					40					45			

Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val

50

55

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
65 70 75 80

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
85 90 95

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
100 105 110

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
115 120 125

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
130 135 140

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
145 150 155 160

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
165 170 175

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
180 185 190

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
195 200 205

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
210 215 220

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
225 230 235 240

Ser Leu Ser Leu Ser Pro Gly Lys
245

<210> 1063

<211> 773

<212> DNA

<213> Artificial sequence

<220>

<223> FC-VEGF ANTAGONIST

<220>

<221> CDS

<222> (4) . . (759)

<223>

<400> 1063

cat	atg	gac	aaa	act	cac	aca	tgt	cca	ccg	tgc	cca	gca	cct	gaa	ctc	48
	Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	
	1				5					10					15	
ctg	ggg	gga	ccg	tca	gtt	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	96
Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	
				20					25					30		
ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	144
Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	
			35					40					45			
agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	192
Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	
		50					55					60				
gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	aac	agc	240
Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	
	65					70					75					
acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	288
Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	
					85					90					95	
aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	336
Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	
				100					105					110		
ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	384
Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	
			115					120					125			
cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	432
Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	
		130					135					140				
gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	480
Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	
	145					150					155					
gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	528
Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	
	160				165					170					175	
cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	576
Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	
				180					185					190		
acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	624
Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	
			195					200					205			
gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	672
Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	
		210					215					220				
ctg	tct	ccg	ggg	aaa	ggg	ggg	ggg	ggg	ggg	ggt	gaa	ccg	aac	tgt	gac	720
Leu	Ser	Pro	Gly	Lys	Gly	Gly	Gly	Gly	Gly	Val	Glu	Pro	Asn	Cys	Asp	
	225					230					235					

atc cat gtt atg tgg gaa tgg gaa tgt ttt gaa cgt ctg taactcgagg 769
 Ile His Val Met Trp Glu Trp Glu Cys Phe Glu Arg Leu
 240 245 250

atcc 773

<210> 1064

<211> 252

<212> PRT

<213> Artificial Sequence

<220>

<223> FC-VEGF ANTAGONIST

<400> 1064

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 Page 427

180

190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
195 200 205
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
210 215 220
Ser Pro Gly Lys Gly Gly Gly Gly Gly Val Glu Pro Asn Cys Asp Ile
225 230 235 240
His Val Met Trp Glu Trp Glu Cys Phe Glu Arg Leu
245 250

<210> 1065
<211> 773
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF ANTAGONIST-FC
<220>
<221> CDS
<222> (4)..(759)
<223>

<400> 1065
cat atg gtt gaa ccg aac tgt gac atc cat gtt atg tgg gaa tgg gaa 48
Met Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu 15
tgt ttt gaa cgt ctg ggt ggt ggt ggt ggt gac aaa act cac aca tgt 96
Cys Phe Glu Arg Leu Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys 20 25 30
cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtt ttc ctc 144
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 35 40 45
ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag 192
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 50 55 60
gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag 240
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 65 70 75
ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag 288
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 80 85 90 95

A-527.ST25.txt

ccg	cgg	gag	gag	cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	336
Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	
				100					105					110		
acc	gtc	ctg	cac	cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	384
Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	
			115					120					125			
gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	432
Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	
		130					135					140				
gcc	aaa	ggg	cag	ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	480
Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	
	145					150					155					
cgg	gat	gag	ctg	acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	528
Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	
160					165					170					175	
ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	576
Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	
				180				185						190		
ccg	gag	aac	aac	tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	624
Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	
			195					200					205			
tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	672
Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	
		210					215					220				
cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	720
Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	
	225					230					235					
cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	tct	ccg	ggg	aaa	taactc	gagg		769
His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys				
240					245					250						
atcc																773

<210> 1066

<211> 252

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF ANTAGONIST-FC

<400> 1066

Met	Val	Glu	Pro	Asn	Cys	Asp	Ile	His	Val	Met	Trp	Glu	Trp	Glu	Cys
1				5					10					15	

Phe	Glu	Arg	Leu	Gly	Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	Pro
			20				25						30		

Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe

35

40

45

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 50 55 60
 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
 65 70 75 80
 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 85 90 95
 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 100 105 110
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 115 120 125
 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
 130 135 140
 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 145 150 155 160
 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 165 170 175
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 180 185 190
 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 195 200 205
 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 210 215 220
 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 225 230 235 240
 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 245 250

<210> 1067

<211> 748

<212> DNA

<213> Artificial Sequence

<220>

<223> FC MMP INHIBITOR

<220>

<221> CDS

<222> (4)..(732)

<223>

<400> 1067

cat	atg	gac	aaa	act	cac	aca	tgt	cca	cct	tgt	cca	gct	ccg	gaa	ctc	48
	Met	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	
	1				5					10					15	
ctg	ggg	gga	ccg	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	96
Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	
				20					25					30		
ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	144
Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	
			35					40					45			
agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	192
Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	
		50					55					60				
gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	aac	agc	240
Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	
	65					70					75					
acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg	ctg	288
Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	
					85					90					95	
aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca	gcc	336
Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	
				100					105					110		
ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa	cca	384
Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	
			115					120					125			
cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac	cag	432
Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	
		130					135					140				
gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	480
Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	
	145					150					155					
gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	528
Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	
	160				165					170					175	
cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	576
Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	
				180					185					190		
acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	624
Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	
			195					200					205			
gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	672
Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	
		210					215					220				

ctg tct ccg ggt aaa ggt gga ggt ggt ggt tgc acc acc cac tgg ggt 720
 Leu Ser Pro Gly Lys Gly Gly Gly Gly Cys Thr Thr His Trp Gly
 225 230 235

ttc acc ctg tgc taatggatcc ctcgag 748
 Phe Thr Leu Cys
 240

<210> 1068

<211> 243

<212> PRT

<213> Artificial Sequence

<220>

<223> Fc MMP INHIBITOR

<400> 1068

Met Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
 1 5 10 15

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 20 25 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 35 40 45

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 65 70 75 80

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
 100 105 110

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 145 150 155 160

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 165 170 175

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 180 185 190

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 210 215 220

Ser Pro Gly Lys Gly Gly Gly Gly Gly Cys Thr Thr His Trp Gly Phe
 225 230 235 240

Thr Leu Cys

<210> 1069

<211> 763

<212> DNA

<213> Artificial sequence

<220>

<223> MMP INHIBITOR-FC

<220>

<221> CDS

<222> (4)..(753)

<223>

<400> 1069

cat	atg	tgc	acc	acc	cac	tgg	ggg	ttc	acc	ctg	tgc	ggg	gga	ggc	ggg	48
	Met	Cys	Thr	Thr	His	Trp	Gly	Phe	Thr	Leu	Cys	Gly	Gly	Gly	Gly	
	1				5					10					15	

ggg	gac	aaa	ggg	gga	ggc	ggg	ggg	gac	aaa	act	cac	aca	tgt	cca	cct	96
Gly	Asp	Lys	Gly	Gly	Gly	Gly	Gly	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	
			20						25					30		

tgc	cca	gca	cct	gaa	ctc	ctg	ggg	gga	ccg	tca	gtt	ttc	ctc	ttc	ccc	144
Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	
			35				40						45			

cca	aaa	ccc	aag	gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	192
Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	
		50					55					60				

tgc	gtg	gtg	gtg	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	240
Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	
	65					70					75					

tgg	tac	gtg	gac	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	288
Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	

80		85		90		95										
gag	gag	cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	336
Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	
				100					105					110		
ctg	cac	cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	384
Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	
			115					120					125			
aac	aaa	gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	432
Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	
		130					135					140				
ggg	cag	ccc	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	480
Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	
	145					150					155					
gag	ctg	acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	528
Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	
160					165					170				175		
tat	ccc	agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	576
Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	
				180				185						190		
aac	aac	tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	624
Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	
			195					200					205			
ttc	ctc	tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	672
Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	
		210					215					220				
aac	gtc	ttc	tca	tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	720
Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	
	225					230					235					
acg	cag	aag	agc	ctc	tcc	ctg	tct	ccg	ggt	aaa	taatggatcc					763
Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys						
240					245				250							

<210> 1070

<211> 250

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR-Fc

<400> 1070

Met Cys Thr Thr His Trp Gly Phe Thr Leu Cys Gly Gly Gly Gly Gly
1 5 10 15

Asp Lys Gly Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys
20 25 30

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Page 434

35

40

45

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 50 55 60

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 65 70 75 80

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 85 90 95

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 100 105 110

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 115 120 125

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 130 135 140

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 145 150 155 160

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 165 170 175

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 180 185 190

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 195 200 205

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 210 215 220

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 225 230 235 240

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 245 250

<210> 1071

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1071

Cys Gly Arg Glu Cys Pro Arg Leu Cys Gln Ser Ser Cys
1 5 10

<210> 1072

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1072

Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys
1 5 10

<210> 1073

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1073

Cys Leu Ser Gly Ser Leu Ser Cys
1 5

<210> 1074

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1074

Asn Gly Arg Ala His Ala
1 5

<210> 1075

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1075

Cys Asn Gly Arg Cys
1 5

<210> 1076

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1076

Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> 1077

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1077

Cys Gly Ser Leu Val Arg Cys
1 5

<210> 1078

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1078

Arg Thr Asp Leu Asp Ser Leu Arg
1 5

<210> 1079

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1079

Gly Asp Leu Asp Leu Leu Lys Leu Arg Leu Thr Leu
1 5 10

<210> 1080

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1080

Gly Asp Leu His Ser Leu Arg Gln Leu Leu Ser Arg
1 5 10

<210> 1081

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1081

Arg Asp Asp Leu His Met Leu Arg Leu Gln Leu Trp
Page 438

1

5

<210> 1082

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1082

Ser Ser Asp Leu His Ala Leu Lys Lys Arg Tyr Gly
1 5 10

<210> 1083

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1083

Arg Gly Asp Leu Lys Gln Leu Ser Glu Leu Thr Trp
1 5 10

<210> 1084

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> INTEGRIN-BINDING PEPTIDE

<400> 1084

Arg Gly Asp Leu Ala Ala Leu Ser Ala Pro Pro Val
1 5 10

<210> 1085

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1085

Arg Gly Trp Val Glu Ile Cys Val Ala Asp Asp Asn Gly Met Cys Val
1 5 10 15

Thr Glu Ala Gln
20

<210> 1086

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1086

Gly Trp Asp Glu Cys Asp Val Ala Arg Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Ala Gly Val

<210> 1087

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1087

Arg Gly Trp Val Glu Ile Cys Glu Ser Asp Val Trp Gly Arg Cys Leu
1 5 10 15

<210> 1088

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1088

Arg Gly Trp Val Glu Ile Cys Glu Ser Asp Val Trp Gly Arg Cys Leu
1 5 10 15

<210> 1089

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1089

Gly Gly Asn Glu Cys Asp Ile Ala Arg Met Trp Glu Trp Glu Cys Phe
1 5 10 15

Glu Arg Leu

<210> 1090

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> VEGF-ANTAGONIST

<400> 1090

Arg Gly Trp Val Glu Ile Cys Ala Ala Asp Asp Tyr Gly Arg Cys Leu
1 5 10 15

<210> 1091

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<220>

<221> misc_feature

<222> (6)..(6)

<223> Xaa = any amino acid

<400> 1091

Cys Leu Arg Ser Gly Xaa Gly Cys
1 5

<210> 1092

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<220>

<221> misc_feature

<222> (2, 3, 8)..(9)

<223> Xaa = any amino acid.

<400> 1092

Cys Xaa Xaa His Trp Gly Phe Xaa Xaa Cys
1 5 10

<210> 1093

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<220>

<221> misc_feature

<222> (2)..(4)

<223> Xaa = any amino acid

<400> 1093

Cys Xaa Pro Xaa Cys
1 5

<210> 1094

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<400> 1094

Cys Arg Arg His Trp Gly Phe Glu Phe Cys
1 5 10

<210> 1095

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR

<400> 1095

Ser Thr Thr His Trp Gly Phe Thr Leu Ser
1 5 10

<210> 1096

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> CTLA4-MIMETIC

<400> 1096

Cys Ser Leu His Trp Gly Phe Trp Trp Cys
 1 5 10

<210> 1097

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> CARBOHYDRATE (GD1 ALPHA) MIMETIC

<400> 1097

Trp His Trp Arg His Arg Ile Pro Leu Gln Leu Ala Ala Gly Arg
 1 5 10 15

<210> 1098

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1098

Leu Lys Thr Pro Arg Val
 1 5

<210> 1099

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1099

Asn Thr Leu Lys Thr Pro Arg Val
 1 5

<210> 1100

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1100

Asn Thr Leu Lys Thr Pro Arg Val Gly Gly Cys
1 5 10

<210> 1101

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1101

Lys Asp Lys Ala Thr Phe
1 5

<210> 1102

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1102

Lys Asp Lys Ala Thr Phe Gly Cys His Asp
1 5 10

<210> 1103

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1103

Lys Asp Lys Ala Thr Phe Gly Cys His Asp Gly Cys
1 5 10

<210> 1104

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1104

Thr Leu Arg Val Tyr Lys
1 5

<210> 1105

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1105

Ala Thr Leu Arg Val Tyr Lys Gly Gly
1 5

<210> 1106

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> BETA2GPI AB BINDING

<400> 1106

Cys Ala Thr Leu Arg Val Tyr Lys Gly Gly
1 5 10

<210> 1107

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> MEMBRANE-TRANSPORTING

<400> 1107

Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
1 5 10

<210> 1108

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> MEMBRANE-TRANSPORTING

<400> 1108

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly
1 5 10

<210> 1109

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> MEMBRANE-TRANSPORTING

<400> 1109

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu
1 5 10 15

Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
20 25

<210> 1110

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<400> 1110

g ttgaaccga actgtgacat ccatgttatg tgggaatggg aatgttttga acgtctg	57
---	----

<210> 1111

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<400> 1111

cagacgttca aaacattccc attcccacat aacatggatg tcacagttcg gttcaac	57
--	----

<210> 1112

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc-TNA-ALPHA INHIBITORS

<400> 1112

ccgcggatcc attacggacg gtgacccaga gaggtgtttt tgtagtgcgg caggaagtca	60
---	----

ccaccacctc cacctttacc c	81
-------------------------	----

<210> 1113

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<220>

<221> CDS

<222> (1)..(57)

<223>

```

<400> 1113
ggt gaa ccg aac tgt gac atc cat gtt atg tgg gaa tgg gaa tgt ttt      48
Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe
1          5          10          15
gaa cgt ctg      57
Glu Arg Leu

```

<210> 1114

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<400> 1114

```

Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe
1          5          10          15
Glu Arg Leu

```

<210> 1115

<211> 66

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc MMP INHIBITOR

```

<400> 1115
ccgcggatcc attagcacag ggtgaaaccc cagtgggtgg tgcaaccacc acctccacct      60
ttaccc      66

```

<210> 1116

<211> 63

<212> DNA

<213> Artificial Sequence

<220>

<223> MMP INHIBITOR Fc

<400> 1116

gaataacata tgtgcaccac ccactgggggt ttcaccctgt gcggtggagg cggtggggac 60

aaa 63

<210> 1117

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> TNF-ALPHA INHIBITOR Fc

<400> 1117

gaataacata tggacttcct gccgcactac aaaaacacct ctctgggtca ccgtccgggt 60

ggaggcggtg gggacaaaac t 81

<210> 1118

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Fc IL-1 ANTAGONIST

<400> 1118

ccgcggatcc attacagcgg cagagcgtac ggctgccagt aaccgggggt ccattcgaaa 60

ccaccacctc cacctttacc c 81

<210> 1119

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> IL-1 ANTAGONIST Fc

<400> 1119
gaataacata tgttcgaatg gaccccgggt tactggcagc cgtacgctct gccgctgggt 60
ggaggcgggtg gggacaaaac t 81

<210> 1120
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc VEGF ANTAGONIST
<400> 1120
atttgattct agaaggagga ataacatatg gacaaaactc acacatgt 48

<210> 1121
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc VEGF ANTAGONIST
<400> 1121
gtcacagttc ggttcaacac caccaccacc acctttaccc ggagacaggg a 51

<210> 1122
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Fc VEGF ANTAGONIST
<400> 1122
tccctgtctc cgggtaaagg tggtggtggt ggtggtgaac cgaactgtga catc 54

<210> 1123
<211> 39
<212> DNA
<213> Artificial Sequence

<220>

<223> Fc VEGF ANTAGONIST

<400> 1123

ccgcgcatcc tcgagttaca gacgttcaaa acattccca

39

<210> 1124

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> VEGF ANTAGONIST Fc

<400> 1124

atttgattct agaaggagga ataacatatg gttgaaccga actgtgac

48

<210> 1125

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> VEGF ANTAGONIST Fc

<220>

<221> misc_feature

<222> (2)..(2)

<223> Position 2, Xaa is L-lys, D-lys, or an ornithyl residue

<220>

<221> misc_feature

<222> (3)..(3)

<223> Position 3, Xaa is L-tyr, D-tyr, phe, trp, or a p-aminophenylalan
yl residue

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, Xaa is a hydrophobic aliphatic amino acid residue

<220>

<221> misc_feature

<222> (4)..(4)

<223> Position 4, optional attachment to leu, norleucyl, D-ala, Asn-Ser, asn-ser-ile, asn-ser-tyr, asn-ser-ile-leu, asn-ser-tyr-leu, or asn-ser-tyr-leu-asn

<400> 1125

acatgtgtga gttttgtcac caccaccacc acccagacgt tcaaaacatt c 51

<210> 1126

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> VEGF ANTAGONIST Fc

<400> 1126

gaatgttttg aacgtctggg tgggtggtggt ggtgacaaaa ctcacacatg t 51

<210> 1127

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> VEGF ANTAGONIST Fc

<400> 1127

ccgcggatcc tcgagttatt tacccggaga cagggagag 39

<210> 1128

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Butoxycarbonyl group attached to the amino terminus.

<220>

<221> misc_feature

<222> (2, 5, 24 and)..(27)

<223> Tert-butyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (7, 13, 29 and)..(35)

<223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (8 and)..(30)

<223> Trityl group attached to the sidechain.

<220>

<221> misc_feature

<222> (9 and)..(31)

<223> Butoxycarbonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (18)..(18)

<223> 1-(4,4-dimethyl-2,6-dioxo-cyclohexylidene)ethyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (36)..(36)

<223> Methoxy resin attached to the carboxyl terminus.

<400> 1128

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 1129

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Butoxycarbonyl group attached to the amino terminus.

<220>

<221> misc_feature

<222> (2, 5, 24 and)..(27)

<223> Tert-butyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (7, 12, 29 and)..(35)

<223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (8 and)..(30)

<223> Trityl group attached to the sidechain.

<220>

<221> misc_feature

<222> (9 and)..(31)

<223> Butoxycarbonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (36)..(36)

<223> Methoxy resin attached to the carboxyl terminus.

<400> 1129

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 1130

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (1)..(1)

<223> Butoxycarbonyl group attached to the amino terminus.

<220>

<221> misc_feature

<222> (2, 5, 24 and)..(27)

<223> Tert-butyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (7, 13, 29 and)..(35)

<223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (8 and)..(30)

<223> Trityl group attached to the sidechain.

<220>

<221> misc_feature

<222> (9 and)..(31)

<223> Butoxycarbonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (18)..(18)

<223> Bromoacetyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (36)..(36)

<223> Methoxy resin attached to the carboxyl terminus.

<400> 1130

Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala	Gly	Gly
1				5					10					15	

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 1131

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (18)..(18)

<223> Bromoacetyl group attached to the sidechain.

<400> 1131

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35

<210> 1132

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<220>

<221> misc_feature

<222> (2, 5, 24 and)..(27)

<223> Tert-butyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (7, 13, 29 and)..(35)

<223> 2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (8, 18 and)..(30)

<223> Trityl group attached to the sidechain.

<220>

<221> misc_feature

<222> (9 and)..(31)

<223> Butoxycarbonyl group attached to the sidechain.

<220>

<221> misc_feature

<222> (36)..(36)

<223> Methoxy resin attached to the carboxyl terminus.

<400> 1132

Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu	Ala	Ala	Arg	Ala	Gly	Gly
1				5				10						15	

Gly	Cys	Gly	Gly	Gly	Gly	Ile	Glu	Gly	Pro	Thr	Leu	Arg	Gln	Trp	Leu
		20						25					30		

Ala	Ala	Arg	Ala
		35	

<210> 1133

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> SYNTHETIC SCHEME FOR PREPARATION OF PEGYLATED PEPTIDE

<400> 1133

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu
20 25 30

Ala Ala Arg Ala
35